



# PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

POTIGBOOSIS8

The Patent Office Concept House Cardiff Road

Newport

South Wales NPf0F800 6 JAN 2004

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

22 December 2003

**BEST AVAILABLE COPY** 

## Patents Form 1/77

tents Act 1977 (Rule 16)





Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference P35017GB/TJF

-8 CEC 2002

LONDON

The Patent Office

Cardiff Road Newport South Wales NP9 1RH

2. Patent application number (The Patent Office will fill in this part)

0228538.5

06 DEC 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

MEDICAL RESEARCH COUNCIL 20 PARK CRESCENT LONDON W1N 4AL

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

UNITED KINGDOM

05840624001

4. Title of the invention

# PROTEIN STRUCTURE AND USES THEREOF

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Kilburn & Strode 20 Red Lion Street London WC1R 4PJ

Patents ADP number (if you know it)

125001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number (if you know it)

Date of filing (day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filling date of the earlier application

Number of earlier application

Date of filing (day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer Yes' if:

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body. See note (d) YES

### Patents Form 1/77

Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

96

Claim (s)

9

Abstract

Orawing (s) --- 5

Drawing (s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date 06.12.2002

12. Name and daytime telephone number of person to contact in the United Kingdom

FORD, Timothy James Tel: 020 7539 4200

#### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

#### Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

## Protein Structure and Uses Thereof

The present invention relates to the crystal structure of pRb/E2F<sub>(409-426)</sub> as well as uses of the structure in identifying agents which modulate the binding between pRb and E2F and/or a pRb/E2F<sub>(409-426)</sub> complex, and thus are useful as pharmaceutical agents in the prevention or treatment of proliferative diseases.

The retinoblastoma tumour suppressor protein (pRb) regulates the cell cycle, sponsors differentiation and restrains apoptosis. Dysfunctional pRb is thought to be necessary for the development of most human malignancies.

10

15

20

pRb controls the cell cycle and apoptosis by acting as a negative regulator of transcription. It is now established that the growth-inhibitory effects of pRb are dependent on its regulation of the E2F family of transcription factors whose activity is necessary for the expression of genes involved in the G1 to S transition of the cell cycle and DNA replication. The transcriptional repression exerted by pRb over E2F responsive promoters involves at least three, distinct mechanisms. By binding to the transcriptional activation domain of E2F, pRb prevents it from recruiting components of the transcriptional apparatus and, once tethered to E2F promoters, pRb interacts with, and represses, other nearby transcription factors. Finally, pRb recruits protein factors to E2F promoters, such as histone deacetylases (HDACs) and histone methyltransferases (HMTases) that negatively regulate transcription by altering chromatin structure.

In addition to regulating entry into S-phase, it is thought that pRb is important in protecting differentiating cells from apoptosis. Certainly in many types of tissue, loss of pRb leads to apoptosis. This and other data has led to a model whereby the anti-apoptotic activity of pRb is mediated by its repression of certain E2F-dependent promoters. Unrepressed E2F is able to drive apoptosis by both p53-dependent and p53-independent mechanisms.

Although inactivation of the pRb pathway is thought to be widely involved in cellular transformation, there are examples of tumours where over-expression of functional pRb appears to be detrimental to successful clinical treatment. For example, adenocarcinoma of the pancreas is the fifth most common cause of cancer-related death in the Western world. It is particularly resistant to currently available forms of chemotherapy and radiation therapy. It is thought that this malignancy is able to evade apoptosis induced by treatment with chemotherapeutic drugs because of over-expression of pRb. It seems plausible that the protective effect of pRb over-expression against apoptosis is mediated by E2F. By blocking transcriptional activation by E2F, over-expression of pRb appears to render pancreatic cancer cells insensitive to chemotherapy.

5

10

15

20

25

**3**0

As many of the anti-tumourigenic properties of pRb are mediated by its regulation of the E2F transcription factors, it would be beneficial to have a crystal structure of the pRb-binding fragment of E2F (E2F<sub>(409-426)</sub>) in complex with the tumour suppressor protein. Such detailed knowledge of the molecular interactions between E2F and the A/B interface of pRb would enable the development of compounds that bind to pRb and inhibit complex formation. Such a compound, administered in parallel with conventional chemotherapy, would offer a means of enhancing treatment of proliferative diseases such as pancreatic cancer and perhaps related diseases.

Accordingly, the present invention provides the crystal structure of the primary pRb-binding fragment of E2F (E2F<sub>(409-426)</sub>) in complex with the tumour suppressor protein pRb. The structure shows how E2F<sub>(409-426)</sub> binds at the interface of the A and B domains of the pocket of pRb making extensive interactions with conserved residues from both.

In order to address the regulation of the E2F transcription factor by pRb, the present inventors have determined the crystal structure of the complex of pRb<sub>AB</sub> bound to the

minimal binding region of E2F, namely E2F<sub>(409-426)</sub>. The structure has important implications for the understanding of pRb/E2F function. The studies have quantified the contribution of the principal interaction made by E2F through residues 409-426 with pRb as well as that of a secondary interaction involving the marked box region of E2F. In both cases these interactions are with the pocket region of the tumour suppressor-protein pRb.

The analysis of the crystal structure of pRb/E2F<sub>(409-426)</sub> suggests that E2F<sub>(409-426)</sub> acts as a sensor of the structural integrity of the pRb pocket. Accordingly, cells in many tissues should be protected against deleterious mutations in pRb because they will sponsor increased E2F transcriptional activation, and thus apoptosis. It seems particularly intriguing, therefore, that all tumour derived pRb mutants fail to bind to E2F suggesting that an intense selectionary pressure operates in many types of tissue in favour of cells which harbour defects in apoptosis once they have lost normal pRb function. Perhaps the most notable exception to this process occurs in retinal cells, which are able to survive for some time with loss of pRb without acquiring other genetic alterations. Indeed, it has been suggested that these particular cells are distinguished by their ability to acquire survival signals from neighbouring cells and thus give rise to the eponymous retinoblastomas.

20

ĬÒ

15

According to a first aspect, the present invention provides a crystal structure of the pRb/E2F<sub>(409-426)</sub> complex, characterised by the atomic co-ordinates of Annex 1.

Preferably the interactions between E2F<sub>(409-426)</sub> and pRb comprise one or more of the following interactions:

E2F <sub>(409-426)</sub> residue	pRb residue
Leu <sub>409</sub>	Lys <sub>548</sub>
Tyr <sub>411</sub>	Glu <sub>551</sub>

E2F <sub>(409-426)</sub> residue	pRb residue								
Tyr <sub>411</sub>	Ile <sub>532</sub>								
Tyr <sub>411</sub>	Glu <sub>554</sub>								
His <sub>412</sub>	Arg <sub>656</sub>								
His <sub>412</sub>	Lys <sub>653</sub>								
Gly <sub>414</sub>	Glu <sub>533</sub>								
Gly <sub>414</sub>	Lys <sub>652</sub>								
Leu <sub>415</sub>	Leu <sub>649</sub>								
Leu <sub>415</sub>	Glu <sub>553</sub>								
Leu <sub>415</sub>	Lys <sub>537</sub>								
Glu <sub>417</sub>	Lys <sub>537</sub>								
Gly <sub>418</sub>	Arg <sub>467</sub>								
Glu <sub>419</sub>	Thr <sub>645</sub>								
Arg <sub>422</sub>	Glu <sub>464</sub>								
Asp <sub>423</sub>	Arg <sub>467</sub>								
Leu <sub>424</sub>	Lys <sub>530</sub>								
Phe <sub>425</sub>	Phe <sub>482</sub>								
Phe <sub>425</sub>	Lys <sub>475</sub>								

In a second aspect, the present invention provides an assay to identify an agent which modulates the interaction between pRb and E2F<sub>(409-426)</sub>, the assay comprising:-

- a) combining together pRb, E2F<sub>(409-426)</sub> and an agent, under conditions in which pRb and E2F<sub>(409-426)</sub> form a complex;
  - b) obtaining a crystal structure of any pRb/E2F(409-426) complex; and
  - c) analysing the crystal structure to determine whether the agent is an agent which modulates the interaction between pRb and E2F<sub>(409-426)</sub>.

In the present invention, the term "modulates" is intended to refer to inhibiting, enhancing, destabilising and/or stabilising the interaction between pRb and E2F<sub>(409-426)</sub> and/or the formation of the pRb/E2F<sub>(409-426)</sub> complex and/or the stability of the complex after formation.

5

"conditions in which pRb and E2F<sub>(409-426)</sub> can form a complex" are those conditions in which pRb and E2F<sub>(409-426)</sub> form a complex in the absence of an agent. Therefore the effect of the agent on the interaction between pRb and E2F<sub>(409-426)</sub> and complex formation can be assessed.

10

15

20

30

In the assay, the combining of the pRb,  $E2F_{(409-426)}$  and agent may be in any order. The order may be combining pRb with the agent and then adding the  $E2F_{(409-426)}$ . Alternatively, the order may be combining  $E2F_{(409-426)}$  with the agent and then adding pRb, or combining pRb with  $E2F_{(409-426)}$  and then the agent. For example, the pRb may be combined with  $E2F_{(409-426)}$  before soaking the complex in the agent, preferably in a solution of the agent. In this regard, two of the pRb,  $E2F_{(409-426)}$  and agent may be co-crystalised before adding the pRb,  $E2F_{(409-426)}$  or agent, as appropriate.

In a third aspect, the present invention provides a method of identifying an agent that modulates a pRb/E2F<sub>(409-426)</sub> complex, comprising selecting an agent using the three-dimensional atomic coordinates of Annex 1.

Preferably, said selection is performed in conjunction with computer modeling.

- 25 Preferably the method comprises the further steps of:
  - a) contacting the selected agent with pRb and E2F<sub>(409-426)</sub> under conditions in which pRb and E2F<sub>(409-426)</sub> can form a complex; and
  - b) measuring the binding affinity of pRb to E2F<sub>(409-426)</sub> in the presence of the agent and comparing the binding affinity to that of pRb to E2F<sub>(409-426)</sub> when in the absence of the agent, wherein an agent modulates a pRb/E2F<sub>(409-426)</sub> complex

when there is a change in the binding affinity of pRb to  $E2F_{(409-426)}$  when in the presence of the agent.

# The method may further comprise:

- a) growing a supplementary crystal from a solution containing pRb and E2F<sub>(409-426)</sub>
   426) and the selected agent where said agent changes the binding affinity of the pRb/E2F<sub>(409-426)</sub> complex under conditions in which pRb and E2F<sub>(409-426)</sub> can form a complex;
- b) determining the three-dimensional atomic coordinates of the supplementary crystal by X-ray diffraction using molecular replacement analysis;
- c) selecting a second generation agent using the three-dimensional atomic coordinates determined for the supplementary crystal.

Preferably, said selection is performed in conjunction with computer modeling.

In a fourth aspect there is provided a method of identifying an agent that modulates a pRb/E2F<sub>(409-426)</sub> complex, comprising:

- a) contacting a selected agent with pRb and E2F<sub>(409-426)</sub> under conditions in which pRb and E2F<sub>(409-426)</sub> can form a complex; and
- b) measuring the binding affinity of pRb to E2F<sub>(409-426)</sub> in the presence of the agent and comparing the binding affinity to that of pRb to E2F<sub>(409-426)</sub> when in the absence of the agent, wherein an agent modulates a pRb/E2F<sub>(409-426)</sub> complex when there is a change in the binding affinity of pRb to E2F<sub>(409-426)</sub> when in the presence of the agent.

There is a "change in the binding affinity" when the binding affinity either decreases or increases when in the presence of the agent. If a decrease is observed, the agent may be inhibiting the complex. If an increase is observed, the agent may be enhancing the complex.

25

5

10



- a) growing a supplementary crystal from a solution containing pRb and E2F<sub>(409-426)</sub> and the selected agent where said agent changes the binding affinity of the pRb/E2F<sub>(409-426)</sub> complex under conditions in which pRb and E2F<sub>(409-426)</sub> can form a complex;
- -b) determining the three-dimensional atomic coordinates of the supplementary crystal by X-ray diffraction using molecular replacement analysis;
- c) selecting a second generation agent using the three-dimensional atomic coordinates determined for the supplementary crystal

Preferably, said selection is performed in conjunction with computer modeling.

In a fifth aspect, the present invention provides a method of identifying an agent that modulates a pRb/E2F<sub>(409-426)</sub> complex, comprising:

- 15 a) selecting an agent;
  - b) co-crystalising pRb with the agent;
  - c) determining the three dimensional coordinates of the pRb-agent association by X-ray diffraction using molecular replacement analysis; and
  - d) comparing the three dimensional coordinates with those of the complex as claimed in claim 1.

In a sixth aspect, the present invention provides a method of identifying an agent that modulates a pRb/E2F<sub>(409-426)</sub> complex, comprising:

- a) selecting an agent;
- 25 b) crystalising pRb and soaking the agent into the crystal;
  - c) determining the three dimensional coordinates of the pRb-agent association by X-ray diffraction using molecular replacement analysis; and
  - d) comparing the three dimensional coordinates with those of the complex as claimed in claim 1.

10

In a seventh aspect, the present invention provides a method of identifying an agent that modulates a pRb/E2F<sub>(409-426)</sub> complex, comprising:

- a) selecting an agent;
- b) co-crystalising pRb, E2F<sub>(409-426)</sub> and the agent;
- 5 c) determining the three dimensional coordinates of the pRb-E2F-agent association -----by-X-ray-diffraction using-molecular-replacement analysis; and
  - d) comparing the three dimensional coordinates with those of the complex as claimed in claim 1.
- In an eighth aspect, the present invention provides a method of identifying an agent that modulates a pRb/E2F<sub>(409-426)</sub> complex, comprising:
  - a) selecting an agent;

- b) co-crystalising pRb and E2F<sub>(409-426)</sub> and soaking the agent into the crystal;
- c) determining the three dimensional coordinates of the pRb-E2F-agent association by X-ray diffraction using molecular replacement analysis; and
- d) comparing the three dimensional coordinates with those of the complex as claimed in claim 1.
- Preferably the method of the fifth, sixth, seventh or eighth aspect further comprises selecting a second generation agent using the three dimensional atomic coordinates determined. The agent is preferably selected using the three dimensional atomic coordinates of Annex 1. The selection may be performed in conjunction with computer modeling.
- Preferably the selected agent and/or the second generation agent, in the second, third, fourth, fifth, sixth, seventh and/or eighth aspects mimics a structural feature of E2F<sub>(409-426)</sub> when said E2F<sub>(409-426)</sub> is bound to pRb.
- Preferably soaking refers to the pRb/E2F<sub>(409-426)</sub> complex being transferred to a solution containing the selected agent.

The method as defined in the third aspect preferably comprises the further steps of:

- a) contacting the selected agent with the pRb/E2F(409-426) complex; and
- b) determining whether the agent affects the stability of the complex.

Preferably-the determination is with fluorescence polarization.

In a ninth aspect, the present invention provides a method of identifying an agent that modulates a pRb/E2F<sub>(409-426)</sub> complex, comprising:

- a) contacting a fluorescently tagged E2F<sub>(409-426)</sub> peptide (E2F-fluoropeptide) with pRb to allow pRb/E2F-fluoropeptide complex formation;
  - b) detecting the fluorescence polarization;
  - c) adding a selected agent; and

5

15

20

d) detecting the fluorescence polarization in the presence of the agent.

In a tenth aspect, the present invention provides a method of identifying an agent that modulates a pRb/E2F<sub>(409-426)</sub> complex, comprising;

- a) contacting a fluorescently tagged E2F<sub>(409-426)</sub> peptide (E2F-fluoropeptide) with pRb to allow pRb/E2F-fluoropeptide complex formation and detecting the fluorescence polarization;
- b) contacting a selected agent with pRb and E2F<sub>(409-426)</sub> peptide (E2F-fluoropeptide) under conditions in which pRb and E2F-fluoropeptide can form a complex, and detecting the fluorescence polarization; and
- c) comparing the fluorescence polarization detected in a) and b).

Preferably a decrease in fluorescence polarization in the presence of the agent indicates that the agent destabilises the complex.

The methods of the ninth or tenth aspects may comprise the further step of adding untagged E2F<sub>(409-426)</sub> and detecting fluorescence polarization.

Preferably if fluorescence polarization decreases, on addition of the untagged E2F<sub>(409-426)</sub>, the agent does not stabilise the complex.

Preferably if there is no substantial change in fluorescence polarization, on addition of the untagged E2F<sub>(409-425)</sub>, the agent-stabilises the complex.

The binding affinities may be measured by isothermal titration calorimetry.

Alternatively the binding affinities may be measured by Surface Plasmon Resonance (SPR).

10

15

In an eleventh aspect, the present invention provides an agent identified by a method according to the second, third, fourth, fifth, sixth, seventh, eighth, ninth and/or tenth aspects of the invention.

In a twelfth aspect, the present invention provides an agent, as set out according to the eleventh aspect of the invention, for use as an apoptosis promoting factor in the prevention or treatment of proliferative diseases.

20 Preferably the, or each selected agent is obtained from commercial sources or is synthesised. Preferably the agent is for use in preventing or treating cancer, which may be pancreatic cancer and related diseases.

In a thirteenth aspect, the present invention provides the use of an agent, which modulates a pRb/E2F<sub>(409-426)</sub> complex, identified by a method according to the second, third, fourth, fifth, sixth, seventh, eighth, ninth and/or tenth aspects of the present invention, in the manufacture of a medicament for the prevention or treatment of proliferative diseases.

The proliferative diseases may be cancer, preferably pancreatic cancer and related diseases.

In a fourteenth aspect, the present invention provides the use of the atomic coordinates of the crystal structure as set out according to the first aspect of the present invention, for identifying an agent-that modulates a pRb/E2F<sub>(409-426)</sub> complex.

In a fifteenth aspect, the present invention provides computer readable media comprising a data storage material encoded with computer readable data, wherein said computer readable data comprises a set of atomic co-ordinates of the pRb/E2F<sub>(409-426)</sub> complex according to Annex 1 recorded thereon.

The present invention will now be described, by way of example only, and with reference to the following figures, in which:

Annex I.

10

15

Atomic co-ordinates for crystal of pRb/E2F(409-426) complex.

In Annex 1 there is shown:

Column Number	Description
2	Atom number
3	Atom type
4	Residue type
. 5	pRb domains (A or B) or E2F <sub>(409-426)</sub> (P)
6	Residue number
7	x co-ordinate of atom (Å)
8	y co-ordinate of atom (Å)
9	z co-ordinate of atom (Å)
10	Occupancy
. 11	B-factor (Å <sup>2</sup> )

## Figure 1.

5

10

Structure of pRb/E2F.

- (A) Schematic drawing of functional domains and protein constructs used for pRb, E2F. The shading used for the constructs in this panel match those used in subsequent figures.
- (B) The structure of pRb<sub>AB</sub>/E2F<sub>(409-426)</sub>, shown in two orthogonal views in Ribbons representation. The helices of the A domain are shown as a darker shade to those of the B domain. The main-chain trace of E2F is labelled.
- (C) The interactions between E2F<sub>(409-426)</sub> and pRb<sub>AB</sub> are shown schematically with the E2F peptide running down the centre. Residues of E2F that are conserved across the five family members are shown as ovals, while the five residue subset of these conserved residues whose mutation leads to disruption of the pRb/E2F interaction are shaded. Hydrogen-bond interactions are shown as broken lines, while hydrophobic contacts are indicated by bands. Residues from domain A of pRb are labelled with an asterisk and the other residues are from domain B. All of the pRb residues shown are either invariant or conserved across 27 species of pRb, p107 and p130.

## 20 Figure 2.

Isothermal Titration Calorimetry (ITC) measurements.

- (A) The upper panel shows the raw data of an ITC experiment performed at 22°C. The lower panel shows the integrated heat changes, corrected for the heat of dilution, and the fitted curve based on a single site model. The panel represents the experiment where E2F<sub>(243-437)</sub> is titrated into Rb<sub>AB</sub>.
- (B) Summary of dissociation constants obtained by ITC measurements. The quoted errors are those produced by fitting the data to a two-state model. For the interaction of E2F<sub>(243-437)</sub> to Rb<sub>AB</sub> and Rb<sub>ABC</sub> the affinities are too high to measure reliably and we have therefore quoted the upper limits of the dissociation constants.

# Structure determination of pRb/E2F

For crystallisation we used a pRb construct based on that previously described by Lee, J.O., Russo, A.A., and Pavletich, N.P. (1998). Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7, Nature 391, 859-65, which has engineered thrombin cleavage sites at the ends of the flexible linker region between the A and B domains. Purification and proteolysis produces a final protein containing residues 372 to 589 of the A domain and 636 to 787 of the B domain (hereafter pRb<sub>AB</sub> - Figure 1A). Although these two domains are not covalently attached after thrombin treatment, they remain tightly associated. The removal of the A-B linker region facilitates crystallisation of pRb but does not alter its binding affinity for E2F. Crystals of the pRb/E2F<sub>(409-426)</sub> complex grew in a plate-like habit with typical dimensions 200 x 200 x 10 µm<sup>3</sup>. Repeated attempts at data collection from flash-cooled crystals using synchrotron X-ray sources were thwarted by very high crystal mosaicity and poor data reduction statistics. The problem was overcome by using the micro-focus diffractometer on station ID13 at ESRF current experience and plans at EMBL and ESRF/ID13, Acta Crystallogr D 55, 1765-1770), currently the only such device installed at a synchrotron source. Using a 10x10 µm<sup>2</sup> aperture, data were collected from four separate and widely spaced volumes of a single crystal in order to minimise radiation damage. A total of 100, 1° oscillation images were collected using a MAR CCD detector. These data extended to a Bragg spacing of 2.5 Å with an overall  $R_{\text{merge}} = 9.2\%$ , and completeness of 87%. The structure was solved by molecular replacement and produced initial electron density maps in which the E2F peptide (E2F<sub>(409-426)</sub>) could be readily located.

# Protein constructs.

10

15

20

25

Rb<sub>AB</sub> was expressed as a GST-fusion protein in *E. coli* using the pGEX-6P vector. The construct was engineered to contain a Prescission protease site at the N-terminus of Rb as well as two thrombin sites (LVPRGS) inserted at either end of the flexible

A-B linker. Fusion protein was loaded onto a glutathione Sepharose 4B column before treatment with thrombin and Prescission protease. The resulting eluent was further purified using a Superdex 200 gel filtration column. Rb<sub>ABC</sub> was expressed in *E. coli* with a C-terminal His-tag using pET-24. Crude lysate was first purified using an S-sepharose column followed by a Ni-NTA step before being run on a Superdex 200 gel filtration column. Recombinant human E2F1<sub>(243-437)</sub> was expressed in *E. coli* using pGEX-6P with an engineered Prescission protease site at the N-terminus of E2F. Crude lysate was bound onto a glutathione Sepharose 4B column prior to cleavage with the protease. The resulting eluent was further purified by gel filtration on a Superdex 75 column. E2F<sub>(409-426)</sub> and E2F<sub>(380-437)</sub> were synthetic peptides. HPV-16 E7<sub>(17-98)</sub> was prepared as described elsewhere (Clements, A.J., K, Mazzareli, J.M. Ricciardi, R.P. Marmorstein R. (2000). Oligomerization properties of the viral oncoproteins adenovirus E1A and human papillomavirus E7 and their complexes with the retinoblastoma protein., Biochemistry 39, 16033-16045).

# Crystallography.

Plate-like crystals were grown by the hanging drop vapour diffusion method at 4°C. Rb<sub>AB</sub> was mixed with the E2F-1 peptide at 1:2 molar ratio and concentrated to 15mg/ml. Hanging drops were formed by mixing 1µl of protein solution with an equal volume of reservoir solution containing; 0.14M Na citrate, 26% PEG400, 4% n-propanol and 0.1M Tris at pH 7.8. Crystals were flash frozen in mother-liquor made up to 25% glycerol. Diffraction data were collected using the micro-focus diffractometer at ESRF and processed using the DENZO and SCALEPACK software (Otwinowski, Z.M., W. (1993). In Data Collection and Processing, L.I. Sawyer, N. Bailey, S., ed. (SERC Daresbury Laboratory), pp. 556-562). Molecular replacement calculations were carried out using Amore (CCP4, 1994) with 1GUX brk as the search model. The final model contains co-ordinates for the protein which cover residues 379-578 of the A domain and 644-787 of the B domain of Rb and the entire E2F<sub>(409-425)</sub> peptide for the four copies present in the asymmetric unit together with 600 solvent

molecules. The refined model has the following residuals;  $R_{work} = 23.7\%$ ,  $R_{free} = 28.7\%$ , rmsd bonds = 0.007 Å, rmsd angles = 1.3°.

# Structure of pRb/E2F complex

- 5 The packing of the A and B domains generates a waist-like interface groove into which E2F<sub>(409-426)</sub> binds in a largely extended manner (Figure 1b). The peptide makes contacts with residues from helices  $\alpha 4$ ,  $\alpha 5$ ,  $\alpha 6$ ,  $\alpha 8$  and  $\alpha 9$  of domain A, and with  $\alpha 11$ from domain B of pRb. Formation of the complex buries 2280 Å<sup>2</sup> of surface area. 1500 Å<sup>2</sup> of which are hydrophobic. The two end regions of the E2F<sub>(409-426)</sub> fragment 10 make extensive contacts with pRb, while interactions made by the middle section of the E2F<sub>(409-426)</sub> fragment (residues 416 to 420) are relatively sparse (Figure 1C). Overall, a high proportion of the hydrogen bond interactions between the two molecules involves the side chains of conserved pRb residues interacting with the main chain of E2F. Examination of the distribution of conserved residues over the 15 surface of pRb, reveals that the majority are accounted for by the E2F binding site. There is a somewhat smaller cluster of conserved residues associated with the LxCxE binding site. Perhaps the most remarkable aspect of this analysis is that although pRb has been reported to associate with at least 110 cellular proteins perhaps 50 or more in a pocket-dependent manner, the E2F and LxCxE binding sites account for almost all 20 of the conserved residues on its surface. There are two explanations that may partially account for these observations. Firstly, many of the reported binding partners of pRb have yet to be verified. Secondly, the LxCxE binding site is probably responsible for mediating the binding of many different proteins, such as HDAC, to pRb.
- Since there are four copies of the pRb/E2F<sub>(409-426)</sub> complex in the asymmetric unit of our crystal form it is possible both to compare these four crystallographically independent copies of the pRb/E2F<sub>(409-426)</sub> complex and to compare them with the crystal structure of pRb/E7 without bond E2F (Lee et al., 1998 Supra). The first six residues at the N-terminus, the α3-α4 and α6-α7 loops adopt different conformations

5

10

15

20

25.

between the four copies in our asymmetric unit, while the variations across the rest of the structure between the four molecules is not significant. Comparison of the pRb structure in the presence and absence of bound E2F<sub>(409-426)</sub> shows that there is essentially no change in the relative orientation of the two lobes of the A/B pocket on E2F<sub>(409-426)</sub> binding nor any widespread changes in the structures of the individual domains. This comparison does reveal that the end of  $\alpha 4$  and the connecting loop to α5 becomes ordered in the pRb/E2F<sub>(409-426)</sub> complex as two conserved residues (Glu464-pRb & Arg467-pRb located towards the end of  $\alpha$ 4 in our structure) interact with the E2F<sub>(409-426)</sub> peptide. Within the E2F<sub>(409-426)</sub> construct there are eight residues that are conserved across E2F's from all animal species (Figure 1A). Amino-acid substitutions at five of these positions have been shown to lead to loss of binding to pRb but retention of E2F's trans-activation potential. The following description focuses on the structural role of these five residues. Tyr(411)-E2F appears to play an important role in peptide binding because its phenolic ring occupies a hydrophobic pocket created by Ile(536)-pRb, Ile(532)-pRb, Ile(547)-pRb and Phe(413)-E2F, while its hydroxyl group makes a hydrogen bond to the invariant Glu(554)-pRb. Towards the C-terminal part of the E2F peptide, Leu(424)-E2F and Phe(425)-E2F make several hydrophobic interactions, two of which involve conserved residues. Leu(424)-E2F makes contacts with the aliphatic portion of the side chain of Lys(530)-pRb and also packs against Leu(415)-E2F and Phe(425)-E2F. In addition, Phe(425)-E2F itself packs against Phe(482)-pRb. Unlike the residues of E2F just discussed, the side-chains of Glu(419)-E2F and Asp(423)-E2F do not point into the groove formed between the A and B domains of pRb, but instead point away from it. Glu(419)-E2F hydrogen bonds through a water molecule with the main-chain carbonyl of Thr(645)-pRb; Asp(423)-E2F forms a salt bridge with Arg(467)-pRb located at the end α4.

Finally, as described earlier, the crystal structure shows how E2F makes extensive contacts with largely conserved residues from both the A and B domains of the pocket

and that the binding site for E2F is dependent on the structure of the interface between the two domains. This feature of the structure suggests that E2F acts as a sensor of the structural integrity of the pRb pocket. The position and nature of the E2F binding site make the binding of the transcription factor particularly sensitive to mutations in the pocket region of the tumour suppressor protein. The potential significance of these observations will be discussed later with regard to the normal role of pRb in protecting cells against E2F-mediated apoptosis.

# Additional determinants of pRb/E2F function

10 It is clear from a number of studies that, although E2F<sub>(409-426)</sub> expressed as a Gal4 fusion protein is sufficient to recruit pRb and repress transcription, there are additional interactions made by the physiologically relevant E2F/DP heterodimer with pRb. Similarly, while the pocket domain is highly conserved, the most frequent site of deleterious mutation, and capable of transcriptional repression, it is not sufficient for the physiological function of pRb. In particular, the C-terminus of pRb is necessary for mediating growth arrest and recruitment of certain cyclin/cdk complexes as well as containing several of the residues whose phosphorylation leads to deactivation of pRb function. Therefore, in order to better understand the requirements for physiological pRb/E2F complex formation, we have made a series of constructs of the two proteins (Figure 1A) and carried out binding measurements by isothermal titration calorimetry (ITC). We have also carried out a series of competition experiments to confirm qualitatively the interpretation of the ITC binding data.

# Isothermal Titration Calorimetry.

Binding of the various E2F constructs to Rb<sub>AB</sub> and Rb<sub>ABC</sub> was measured by isothermal titration calorimetry using a MicroCal Omega VP-ITC machine (MicroCal Inc., Northampton, USA). The E2F constructs at a concentration between 100-150 μM were titrated into 12-15 μM Rb at a temperature of 22°C. Proteins were dialysed against 50mM Tris pH 7.6, 100mM NaCl and 1mM TCEP. After subtraction of the

dilution heats, calorimetric data was analysed using the evaluation software MicroCal Origin v5.0 (MicroCal Software Inc.). For all of the titrations, the stoichiometry of ligand binding to Rb was very close to 1.0. For E2F<sub>(243-437)</sub> binding to Rb, the binding affinity and the heat change associated with binding were such that we could only establish that binding was tighter than 10 nM. In order to verify that binding of this protein was similar for both Rb<sub>AB</sub> and Rb<sub>ABC</sub> we carried out competition experiments which showed approximately equal partition between the two different Rb proteins.

# Competition experiments.

5

10 The proteins used in these experiments were His -Rb ABC (RESIDUES 380-929); MW 66.07kDa, non-tagged RbAB (residues 372-787); MW 48.67 KDa, are His6-RbAB (residues 376-792); MW 49.86 KDa, E2F<sub>(243-437)</sub>; MW 21.45 KDa HPV E7 (residues 17-98); MW 9.38 KDa and E2F<sub>(409-426)</sub>; MW 2.12 KDa. Protein concentrations were carefully determined by u.v. spectroscopy and confirmed by ITC titrations. The small 15 acidic E2F proteins stain much weaker than Rb with Coomassie on SDS-PAGE. For all gel lanes contained a final RbAB concentration of ca. 7 µM. After equilibration with E2F<sub>(243-437)</sub> and E2F<sub>(409-426)</sub> the samples were loaded onto a 1.0ml Ni column and washed with 7 x 0.5 ml of loading buffer (50mM Tris pH 7.5, 200mM NaCl & 10mM Imidazole). The samples were then eluted with 7 x 0.5ml elution buffer (50mM Tris, 20 pH 7.5, 200mM NaCl, 200mM Imidazole). After volume correction samples were boiled in SDS loading buffer and run on a 4-12% SDS PAGE. For the two pRb proteins and E2F<sub>(243-437)</sub> were mixed at 40µM in a final volume of 0.5ml. After equilibration for 2hrs the mixture was loaded onto 1ml Ni beads in a small column, washed with 7 x 0.5ml of loading buffer (50mM Tris, pH 7.5, 200mM NaCl, 10mM 25. Imidazole), eluted using 7 x 0.5ml elution buffer (50mM Tris, pH 7.5, 200mM NaCl. 200mM Imidazole). Samples, after correcting for volume were boiled in SDS sample buffer and run on a 4-12% SDS gel.

A typical ITC experiment is shown in Figure 2A and a summary of the affinity constants obtained for both pRbAB and pRbABC interacting with three constructs of E2F are given in Figure 2B. The two shorter E2F constructs bind to either pRbAB or pRb<sub>ABC</sub> with similar affinities. However, E2F<sub>(243-437)</sub> binds at least 16-fold stronger than either of the two shorter E2F fragments to both pRbAB and RbABC. Our ITC data therefore show that there are additional interactions of the A/B pocket of pRb with a region of E2F-1 outside of the transactivation domain. This result has been confirmed qualitatively by competition experiments which show that a 15-to 30-fold molar excess of the shorter E2F peptide is required to 50% compete with E2F<sub>(243-437)</sub> for binding to pRb. Our results are consistent with an earlier report that noted an interaction of pRb with the marked box region of E2F (residues 245-317). Taken together, these data demonstrate that the majority of the free energy of interaction between pRb and E2F is contributed by the 18-residue segment E2F(409-426) used in our structure analysis. There is an additional stabilising interaction between the marked box region of E2F and pRb, that contributes approximately 2kcal mol<sup>-1</sup> to the overall free energy of complex formation, but is not sufficient on its own for complex formation.

1Ò

15

20

25

As the binding constant for the interaction of E2F<sub>(243-437)</sub> with pRb<sub>AB</sub> (or pRb<sub>ABC</sub>) was too tight to determine reliably by ITC we performed a competition experiment to determine if this E2F construct bound preferentially to one or the other pRb construct. The results show approximately equal partitioning of E2F<sub>(243-437)</sub> between the two pRb species and demonstrates therefore, that the C-terminus of pRb does not participate in the binding to E2F-1 in isolation. This means that in addition to the interaction of E2F<sub>(409-426)</sub> with the pocket region of pRb there is an additional interaction, almost certainly involving the marked box region of E2F, that also binds to the pRb pocket. This data is consistent with the hypothesis that the approximately 10-fold stronger interaction of E2F/DP with pRb<sub>ABC</sub> rather than pRb<sub>AB</sub> reported previously arises through interactions of the DP component of the E2F/DP heterodimer with the C-terminus of pRb. This ideas is strongly supported by the data from another study

which shows that DP-1 interacts with pRb in a manner that does not require the structural integrity of the A/B pocket. Taken together, these data indicate that at least one of the functions of the C-terminus of pRb is to bring additional stabilisation to the interaction of the tumour suppressor with the heterodimeric E2F/DP transcription factors.

## Use of structure atomic co-ordinates of Annex I

The atomic co-ordinates of Annex 1 are cartesian co-ordinates derived from the results obtained on diffraction of a monochromatic beam of X-rays by the atoms of the pRb/ E2F<sub>(409-26)</sub> complex in crystal form. The diffraction data was used to calculate electron density maps of the crystal. The electron density maps were then used to position the individual atoms of the pRb/ E2F<sub>(409-26)</sub> complex.

The determination of the three-dimensional structure of the pRb/E2F<sub>(409-426)</sub> complex provides basis for the design of new and specific agents that modulates formation of the complex and/or modulates the interaction between pRb and E2F<sub>(409-426)</sub>. For example, computer modelling programs may be used to design different molecules expected to modulate formation of the pRb/E2F<sub>(409-426)</sub> complex and/or the interactions between pRb and E2F<sub>(409-426)</sub>.

A candidate agent, may be any available compound. A commercial library of compound structures such as the Cambridge Structural Database would enable computer based *in silico* screening of the databases to enable compounds that may interact with, and/or modulate formation of, the complex to be identified.

Such libraries may be used to allow computer-based high throughput screening of many compounds in order to identify and select those agents with potential to modulate formation of the pRb/E2F<sub>(409-426)</sub> complex and/or the interaction between pRb and E2F<sub>(409-426)</sub>.

-25

5

10

15

In this regard, a potential modulating agent can be subjected to computer modelling with a docking program such as GRAM, DOCK or AUTODOCK (see Walters et al., Drug discovery Today, Vol.3, No. 4, (1998), 160-178, and Dunbrack et al., Folding and Design, 2 (1997) 27-42) to identify and select potential agents. This can include computer fitting of potential modulating agents to the pRb/E2F<sub>(409-426)</sub> complex to ascertain how the agent, in terms of shape and structure, will bind to the complex.

Computer programs can be employed to estimate the interactions between the pRb, E2F<sub>(409-426)</sub> and agent or pRb/E2F<sub>(409-426)</sub> complex and agent. These interactions may be attraction, repulsion, and steric hindrance of the two binding partners (e.g. the pRb/E2F<sub>(409-426)</sub> complex and a selected agent). A potential agent will be expected to be more potent if there is a tighter fit and fewer steric hindrances, and therefore greater attractive forces. It is advantageous for the agent to be specific to reduce interaction with other proteins. This could reduce the occurrence of side-effects due to additional interactions with other proteins.

Potential agents that have been designed or selected possible agents can then be screened for activity as set out in the second to seventh aspects above. The agents can be obtained from commercial sources or synthesised. The agent is then contacted with pRb/E2F<sub>(409-426)</sub> complex to determine the ability of the potential agent to modulate the formation of the complex. Alternatively the agent may be contacted with pRb and E2F<sub>(409-426)</sub> under conditions in which pRb and E2F<sub>(409-426)</sub> can form a complex (in the absence of agent), to determine the ability of the agent to modulate complex formation.

25

10

15

20

A complex of pRb/E2F<sub>(409-426)</sub> and said potential agent can then be formed such that the complex can be analysed by X-ray crystallography to determine the ability of the agent to modulate complex formation and/or the interaction between pRb and E2F<sub>(409-426)</sub>.

The complex of pRb/E2F<sub>(409-426)</sub> and agent could be compared to that for pRb/E2F<sub>(409-426)</sub> alone.

Detailed structural information can then be obtained about the binding of the potential agent to the complex. This will enable the structure or functionality of the potential agent to be altered to thereby to improve binding. The above steps may be repeated as may be required.

5

10

15

20

25

The agent-pRb/E2F<sub>(409-426)</sub> complex could be analysed by co-crystallising pRb/E2F<sub>(409-426)</sub> with the selected agent or soaking the agent into crystals of the pRb/E2F<sub>(409-426)</sub> complex; and then determining the three dimensional co-ordinates of the agent-complex by X-ray diffraction using molecular replacement analysis.

Therefore, the pRb/E2F<sub>(409-426)</sub> -agent complexes can be crystallised and analysed using X-ray diffraction data obtained and processed, for example using the DENZO and SCALEPACK software (Otwinowksi, Z. M., W. (1993).Difference Fourier electron density maps can be calculated based on X-ray diffraction patterns of soaked or co-crystallised pRb/E2F<sub>(409-426)</sub> complex and the solved structure of uncomplexed agent. These maps can then be used to determine the structure of the agent bound to the pRb/E2F<sub>(409-426)</sub> and/or changes in the conformation of pRb/E2F<sub>(409-426)</sub> complex relative to the pRb/E2F<sub>(409-426)</sub> complex in the absence of agent.

The agent may be improved, for example by adding or removing functional groups, substituting groups or altering its shape in light of data obtained from agent bound to pRb/E2F<sub>(409-426)</sub> complex and/or agent bound to pRb. Such an improved agent may then be subjected to the methods of the invention.

Electron density maps can be calculated using programs such Amore from the CCP4 computing package (Collaborative Computational Project 4. The CCP4 Suite:

Programs for Protein Crystallography, Acta Crystallographical, D50, (1994), 760-763).

The provision of computer readable media enables the atomic co-ordinates to be accessed to model the pRb/E2F<sub>(409-426)</sub> complex by, for example, RAMSOL (a publicly available computer software package which allows access and analysis of atomic co-ordinate data for structure determination and/or rational drug design).

In addition, structure factor data, derivable from the atomic co-ordinate data (see e.g. Blundell et al., in Protein Crystallography, Academic Press, New York, London and San Francisco, (1976)), can be used to enable difference Fourier electron density maps to be deduced.

# Screening assays

After an agent has been selected, its inhibitory effect on pRb/E2F<sub>(409-426)</sub> complex formation or ability to interact with the pRb/E2F<sub>(409-426)</sub> complex can be assessed with one or more of the assays of the invention.

For example, the crystal structure of the interaction of E2F<sub>(409-426)</sub> with pRb can be used to aid the design of a fluorescently tagged peptide for the use in a binding assay suitable for high throughput screening of low molecular weight compounds or peptide libraries. The fluorescent tag may be a fluorescein, rhodamine or some other commercially available tag chemically attached via a suitable amine or thiol group.

Binding could be measured by detecting fluorescence polarization in an homogeneous assay format (i.e. one in which all reagents are mixed in a single well, and reaction occurs in solution without wash steps). Fluorescence polarization technology is commonly applied in high throughput screening laboratories (ref: Sokham et al. (1999) Analytical Biochemistry, 275, 156-161. "Analysis of protein-peptide interaction by a

miniaturised fluorescence polarization assay using cyclin-dependent kinase2/cyclin E as a model system.")

Fluorescence polarization can be used to determine binding of a fluorescently-tagged small molecule (ligand or peptide) with a large molecule (receptor or protein) by detecting changes in the rotational velocity of the small molecule in the free and bound state. The rotational velocity is inversely proportional to the size of the molecule. Using suitable optics these changes in rotational velocity can be measured as a differences in light transmitted in parallel and perpendicular to a polarized excitation source.

In the assay of the present invention, fluoro-peptide (E2F<sub>(409-426)</sub>-fluoropeptide) bound to pRb will have a low rotational velocity and will appear stationary during the excitation period. Emitted light will be transmitted in parallel to the polarized incident light and the light detected will have a high polarization value. In contrast in the presence of an inhibitor of the interaction between pRb and E2F<sub>(409-426)</sub>-fluoropeptide, the free E2F<sub>(409-426)</sub>-fluoro-peptide will have a high rotational velocity and light will be transmitted in all directions. Emitted light will be detected both parallel and perpendicular to the polarized excitation source, and will have a low polarization value.

An inhibitor assay could include the following steps:

10


15

.20

- a) allow complex formation of pRb and E2F<sub>(409-426)</sub>-fluoropeptide, and measure maximum fluorescence polarization; and
- b) add a selected agent and detect whether there is a decrease in fluorescence polarization.

Alternatively, an assay could include the steps:

a) allow complex formation of pRb and E2F<sub>(409-426)</sub>-fluoropeptide in the presence and
 30 absence of a selected agent and measure the fluorescence polarization; and



Compounds which stabilise the pRb/E2F<sub>(409-426)</sub> complex could be assessed in a modification of the above assay, involving competition binding of pRb by  $E2F_{(409-426)}$  and  $E2F_{(409-426)}$ -fluoropeptide.

In this regard an assay could include the following steps:

15

- a) allow complex formation of pRb/E2F<sub>(409-426)</sub>-fluoropeptide, and measure max fluorescence polarization;
- b) add a selected agent, if no change in fluorescence polarization there is no disruption of complex;
  - c) add unlabeled E2F<sub>(409-426)</sub> expect displacement of E2F<sub>(409-426)</sub>-fluoropeptide and a decrease in fluorescence polarization, but not if complex is stabilised by presence of the agent.

The interactions could be confirmed by co-crystalisation of pRb/E2F<sub>(409-426)</sub> with the agent, and determination of the three dimensional atomic coordinates by X-ray diffraction and molecular replacement.

The E2F<sub>(409-426)</sub>/pRb interaction can also be applied to heterogeneous assay formats (i.e. ones in which reagents are partitioned between a solid support and in solution, and wash steps are involved). This would involve the immobilisation of pRb on microtitre plates, for example by antibody capture or metal ion chelation using Histagged pRb and Nickel coated plates. E2F<sub>(409-426)</sub> peptide may be tagged with fluorescence as above and the fluorescent detected directly to determine amount bound. Alternatively, the peptide could be labelled with biotin and detected with

Compounds which interact with the complex without altering association or

streptavidin-horse radish peroxidase in an ELISA-like format.

disassociation of the complex could be identified by crystallographic means, unless the agent itself was tagged (radioactivity/fluorescence) and binding to the complex measured directly, eg fluorescence polarization as above or scintallation counting of an immuno-precipitate.

5.

10

15

20

Alternatively, the agent can be added to pRb and E2F<sub>(409-26)</sub> under conditions in which pRb and E2F<sub>(409-26)</sub> can form a complex. This could result in the agent and complex co-crystallising. The binding affinities of pRb to E2F<sub>(409-26)</sub> in the pRb/ E2F<sub>(409-26)</sub> complex in the presence and absence of the agent can then be compared to determine whether the agent inhibits complex formation. The three dimensional structure of the pRb/ E2F<sub>(409-26)</sub> – agent complex can also be solved to enable the associations in the new complex to be compared with those in the pRb/ E2F<sub>(409-26)</sub> complex (see Annex 1). As a further alternative the pRb/ E2F<sub>(409-26)</sub> complex can be formed before soaking the complex in the presence of a selected agent. The binding affinities of pRb to E2F<sub>(409-26)</sub> can then be determined in the presence and absence of the agent. As before, the three dimensional structure of any pRb/ E2F<sub>(409-26)</sub> – agent complex could be solved.

The binding affinities can be measure using isothermal titration calorimetry.

Alternatively, surface plasmon resonance could be used such as that provided by

Biacore AB.

Preferred features of each aspect of the invention are as for each of the other aspects *mutatis mutandis*. The prior art documents mentioned herein are incorporated to the fullest extent permitted by law.

•	٠
ä	l
ä	ľ
LID	ŀ
7	ŀ

27.26 20.09 27.99 19.42 16.89 26.49 37.23 23.54 23.14 21.30 20.05 18.64 17.76 14.99 22.07 16.78 16.27 16.13 15.44 14.45 15.36 33.36 10.08 14.44 17.31 13.51 12.21 20.61 16.60 1.00 1.00 11.00 00. 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 00.1 1.00 1.00 00: 00. 1.00 . 00 1.00 ..00 .00 ..00 1.00 00: 00: 00: 00:1 1.00 27.840 26.050 21.343 25.688 27.085 27.907 29.235 30.06 31.425 20.591 30.147 31.921 28.771 27.128 26.770 27.986 26.989 27.168 25.195 24.033 22.679 26.014 28.039 28.810 29.075 29.241 28.053 26.201 28.771 29.834 29.273 30.071 -6.140 -4.175 -6.895 -7.617 -5.451 -8.842 -9.050 -9.689 -9.957 -10.838 -11.970 -10.306 -6.670 -7.419 -5.976 -4.583 -3.617-4.708 -6.488 -6.115 -6.053 -5.381 -5.561 -7.361 -5.117 -4:152 -5.823 -6.634 -9.970 -4.229 -3.369 .694 6.215 3.278 3.155 .466 7.786 2.769 -0.663 0.895 7.677 4.371 5.894 7.244 7.807 9.205 4.848 4.598 4.253 3.192 2.985 1.260 1.953 1.304 0.500 0.080 .1.472 2.043 2.515 1.641 .0.081 0.815 0.019 386 386 384 384 384 385 385 385 385 385 385 386 386 386 386 386 386 3.84 384 387 387 387 387 387 387 387 388 384 385 385 Ø ď ⋖ Ø GLN GLN GLN LEU LEU LEU GLN GLN GLN LEU MET GLN LEU LEU MET MET MET MEŢ MET MET MET MET MET MET 5 5 5 6 5 5 52 53 54 55 56 559 60 61 62 ATOM ATOM ATOM ATOM. ATOM. ATOM ATOM. ATOM PLOM ATOM

24.310 23.505 23.948 27.084 -1.844 -3.753 -0.146 -I.006 -2.597 0.391 4.043  $\begin{smallmatrix} \mathbf{7} \\ \mathbf{6} \\ \mathbf{6}$ 

:: ::

C	) O	×	יס;	ט	ט	ט	0	z	U	0	×	บ	บ	ບ	ບ	ט	0	N	ט	บ	0	ບ	0	'¤	ບ	บ	ບ	บ	0	0	ບ	0	Z	บ	ບ	ט	0	Z	ŭ	0	. Z
1 00 11 56	1.00 12.74	1.00 10.33	0	0 1	0 14.	0 17.3	1.00 13.52	0 15.3	8.5	7.	7.5	1.00 8.16	6.7		6.7	ω.	0 9.7	4	0.9.9	9.2	0	. 7	00.	.00 12.2	1.00 15.01	.00 16.0	.00 2	。	.00 2	.00 3	.00	Н	Н	0	1.00 17.66	1.00 23.36	0	0	0	1.00 14.83	1.00 11.35
	27.796	و	0	0	9.79		7			2	H	33,102	ω.		H	4	4	ъ.	ø.	ů.	37.719	7		8.38	39.523	ö	•	9.22	ö	37.984	۲.	40.559	40.251	œ	o.		42.555	•	٥.	40.573	æ.
10.030		10.206	1.32	•	.87	•	ω.	•	Ċ.	9.784	11.724	an a	12.675	LJ.	13.040	11.077	11.699	10.162	9.811	8.437	.49	10.829	11.660	0.72	.58	.15	10.725	.91	.87	. 87	11.482	. 44	•	•	8.607	.27	8.543	.74	.67	11.219	ö
	3.497	•	.92	•	.97	•	.61	•	•	•	•	•	6.401	6.360	5.063	4.665	3.600	5.084	4.221	4.561	5.712	4.341	5.208	•	•	•	•	0.312	•	.01	•	•	5.422	•	•	.54	8.739	.71	7.843	8.811	7.747
m		ď	GLN A 395		Ø	Ø	Ø	ø	ď	ø	ø	ø	Ø	PRO A 396 ·	Ø	ø	ø	¥		¥	Ø	Ø	SER A 397	ø	A	ø	ď	Ø	ď	Ø	ď	ø	Ø	Ø	ø	ASN A 399	Ø	Ø	ø	ASN A 399	A 4
	0																						0							•			Z 		g		OD1		ບ	0	z
12.	122	12.	124	125	126	12.	128	125	. 13(	13]	132	133	134	135	136	13,	138	135	140	141	142	143	144	145	146	147	148	145	150	.151	. 152	153	154	155	156	157	158	159	160	161	162
ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM .	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	. ATOM	ATOM	ATOM	ATOM	ATOM

6.89 9.50 110.222 14.322 8.81 8.60 9.20 9.50 10.54 111.31 11.31 12.21 12.21 12.21 13.21 13.21 14.32 15.32 16.32 17 7.17 4.71 2.70 2.00 2.00 2.00 37.981 38.047 36.732 38.665 19.588 10.585 39.816 10.641 15.045 16.024 15.091 16.141 13.157 14.607 15.584 13.744 11.498 11.434 10.307 9.194 8.017 13.941 12.753 15.916 15.264 8.829 8.722 9.965 9.665 111.217 8.933 10.029 7.783 10.145 10.687 10.799 12.231 12.780 13.035 6.360 5.968 8.255 8.347 9.222 14.355 13.546 13.807 12.514 ILE ILE ILE ILE ILE ILE SER SER SER SER SER TYR TYR TYR TYR TYR TYR TYR TYR ILE ILE TYR TYR
TYR
PHE
PHE
PHE
PHE
PHE
PHE 171 172 173 174 175 

13.31 10.19 11.31 12.26 12.84 15.33 18.94 16.26 12.01 13.01 10.65 9.58 7.04 9.92 10.76 9.20 8.76 12.65 11.91 9.61 9.46 10.38 8.49 8.65 9.13 7.79 8.17 7.93 7.49 8.42 8.29 8.28 6.45 7.43 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1111 1.00 1.00 38.979 41.005 41.687 40.757 39.670 42.080 42.813 42.188 43.708 44.505 45.337 44.231 40.629 43.373 39.114 38.388 41.100 41.026 13.158 39.890 42.617 41.316 10.900 42.061 41.004 40.929 41.057 40.955 40.027 18.060 18.036 16.115 18.526 .9.011 16.823 14.902 18.845 21.036 23.859 19.165 19.284 17.366 21.660 22.387 22.403 21.698 16.626 18.520 20.772 24.356 22.573 23.248 23.399 24.215 19.051 22,876 23.974 12.255 11.909 12.696 10.991 10.927 7.272 8.844 12.056 8.446 12.327 12.371 15.190 12.832 16.155 15.245 16.454 16.358 16.056 17.807 17.892 17.326 18.360 17.817 13.861 14.059 16.101 16.871 18.163 20.132 20.746 20.691 18.050 19.606 16.213 15.007 18.625 405 405 405 405 405 405 406 406 406 406 406 406 406 406 407 407 407 407 407 407 408 408 408 408 408 408 408 409 409 409 409 409 ASN A ASN A ASN A CYS A CYS A CYS A CYS A CYS A CYS A THR A CYS A THR A CYS A THR'A VAL A ASN THR VAL VAL VAL VAL VAL VAL ASN ASN ASN 207 208 209 210 211 212 220 222 2223 2223 2224 2224 2229 230 2310 232 233 234 ATOM ATOM ATOM ATOM ATOM ATOM ATOM **NOIV** ATOM ATOM ATOM

17.2 18.3 19.3 1.00 1.00 1.00 11111 18.856 19.221 20.478 20.156 19.867 19.336 21.055 21.858 24.252 24.252 24.221 24.221 23.307 21.398 19.310 19.363 20.915 11. 41.0 11. 47.0 12. 384 11. 422 10. 086 9. 052 9. 052 9. 052 10. 082 10. 082 11. 928 11. 928 11. 928 11. 928 11. 928 11. 928 11. 928 11. 928 11. 928 11. 928 11. 928 11. 928 268 269 270 271 272 273 

7.7.7.7.90 19.286 19.937 22.296 23.738 24.562 24.843 19.111 18.424 17.530 17.084 16.283 17.717 13.052 18.992 16.222 16.381 16.045 9.342 9.498 8.200 9.864 10.838 111.675 112.913 113.990 115.052 115.052 115.052  $\begin{array}{c} 418 \\ 418 \end{array}$ LEU A
LIEU A
LIYS A
ARG A
A 313 314 315 316 316 304 305 306 307 308 308 310 311 

14.81 14.81 15.45 16.45 17.00 17.00 18.33 18.34 19.31 10 18.902 17.114 16.694 17.722 17.729 17.999 19.038 20.653 20.653 16.750 16.527 16.527 11.5.923 13.913 14.638 15.166 12.511 13.895 13.371 13.746 12.986 13.576 12.817 14.901 15.558 17.095 17.772 17.825 18.381 8.834 7.756 6.867 7.330 6.996 6.996 6.996 6.996 7.233 7.274 7.274 7.538 9.208 11.575 11.591 9.931 

12.633 11.739 11.779 12.102 13.535 13.935 9.514 10.489 11.052 10.664 11.526 11.580 12.688 10.870 10.025 12.069 12.462 14.894 14.861 14.955 11.563 11.081 11.339 10.497 11.990 13.958 13.456 4.036 6.8830 6.715 7.364 7.930 6.890 6.890 6.890 8.720 8.720 8.720 8.720 10.831 111.939 114.004 114.004 9.942 9.951 9.753 9.726 8.549 8.518 9.642 10.861 10.903 8.872 9.126 7.651 6,582 5.192 4.705 3.495 3.309 427 427 PHE

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8

1.17.8


1.17.8

1.17.8

1 CANOCAGE CAN 101 

10.41 9.96 13.02 11.76 15.88 18.85 20.32 330.33 332.56 336.99 336.99 336.99 119.79 20.97 1.00 1.00 10.464 9.564 9.5687 10.689 11.558 11.469 7.772 6.897 7.602 6.355 6.355 6.355 4.125 3.537 4.109 4.701 3.842 2.783 4.909 3.522 4.450 5.450 4.830 3.531 2.825 3.404 4.699 7.061 7.061 7.834 7.834 7.119 8.710 8.710 8.710 11.692 112.923 14.009 7.038 5.818 5.439 3.869 4.696 4.656 3.571 3.571 2.537 3.073 3.810 4.512 3.255 3.426 7.907 7.066 6.769 8.239 8.2329 8.469 8.4469 7.334 6.583 5.660 7.448 8.494 8.494 11.123 11.123 11.123 11.228 11.228 11.238 11.238 11.573 11.573 4432 4432 4432 4432 4433 4433 

30.09 28.02 28.75 22.64 18.79 21.55 21.30 22.04 23.35 30.36 26.25 24.75 22.13 24.37 22.50 21.76 27.57 29.99 20.38 21.06 19.36 27.95 18.75 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 -3.115 -3.836 -3.431 7.079 2.729 3.330 4.618 5.796 5.270 9.531 0.952 4.591 4.724 6.426 7.496 5.695 10.061 9.974 10.046 8.591 9.153 9.025 12.283 7.914 11.119 10.760 11.758 11.088 9.129 8.660 7.448 6.874 9.947 9.405 6.535 8.811 6.035 5.510 6.166 5.986 5.639 4.007 5.722 6.064 5.952 6.602 6.142 5.665 6.237 5.115 5.193 4.348 3.450 2.105 4.072 3.652 3.329 1.569 1.081 -0.349 3.675 2.649 6.778 2.979 1.019 1.680 1.801 -0.623 -2.104 4.522 0.383 3.330 3.826 -5.002 1.303 2.080 .0.016 -2.941 0.081 1.098 3.147 -4.398 437 439 439 136 436 436 437 439 439 439 439 440 440 440 440 440 440 æ CYS CYS CYS CYS VAL GLU GLU ILE ILE ILE VAL ILE ILE GLY GLY CG1 CG2 CG2 CG2 CG3 157 158 159 160 162 476 479 480 483 161 467 468 469470 472 £71 478 481 182 9 ATOM ATOM



	. •	<b>5</b>	۲ د	~	0	,	0		
000	) Z	SER	7 T	43	2.940	7.002	 m	0	13.14
	đ	SER	A 4	4	46	. 53	24	1.00	•
502		SER		4	1.049	Н	5.0	0	2
503		SER		4	.07	. 24	4.21	0	7.5
504		SER	-	4	36	. 52	.34	•	2.4
505		SER		4	.86	. 74	7.41	0	2.7
506		GLN	A 4	4	69	.40	6.07	1.00	12.47
507		GLN	<b>A</b>	44	40	.38	7.06	0	٠.
508		GLN	A 4		52	. 24	16.467	1.00	4.
509	٠	GLN	A 4	44	.28	.98	7.40	1.00	ι
510		GLN	A 4	44	7.	.90	8.09	1.00	20.42
511		GLN	A 4	44	.41	.57	H		9.6
512		GLN	A 4	44	.04	.10	7.50	°.	٥.
513		GLN	A 4	44	. 72	.89	7.	1.00	11.87
514		GLN	A 4	4,	.83	. 63	8.8	1.00	9
515		ARG	A 4	4	.76	.83	6.82	0.	o.
516		ARG	A 4	4	. 02	.34	.33	1.00	ī.
517	9	ARG	A 4	45	5.910	.90	6.	1.00	12.33
518	•	ARG	<b>A</b>	4	.31	. 79	5.40	0	°
519		-	A 4	4	.27	.02	4.66	1.00	2.
520	•	ARG	4	4	.59	.08	13.790	0.	7.5
521		ARG	<b>4</b> .	4	.17	.57	2.77	°.	9.6
322		ARG	A 4	4	.47	.44	2.50	٥.	ō.
523	,	ARG	4	4	43	•	2.0	1.00	2.6
524		ARG	₽	4	. 75	٣.	8.23	°.	ο.
325	0	ARG	<b>A</b>	4	. 22	3.973	9.35		⊢.
326	•		<b>4</b>	4	.86	ĸ.	7.76	1.00	9
527	e S	٠.	Α 4		. 50	ø.	8.5	Õ.	٣.
528	G	•	A 4	4	. 44	7.988	7.83	•	õ
529	g	TYR	4	4	13	۰.	8.57		•
530	CD1.	TYR	4	4	8.564		8.55	٠	Η.
531	CE1	TYR	Ą.	46	9.264	٠.	9.24	1.00	٠.
532	CZ	TYR	A 4	4	9.	ø.	9.96	1.00	2.00
333	НО	TYR	¼ 4	4	7	4,	0.55	1.00	4
334	CE2	TYR	4.		.29	1.0	.02		0
335	CD2	TYR	<b>A</b> . 4	4		۰.	9.3	1.00	
336	ບ	TYR	4.4	46	8	7	ō.	1.00	5.32
537	0	TYR	4	4	.61	. 82	0.9	1.00	3.64
538	N	LYS	₽. 4		.56	699.9	20.054	1.00	3.91
539	ð	LYS	4.	47	œ	ø.	ű	1.00	3.14
540	CB	LYS	4		.33	, 50	1.1	1.00	Н

21.677 21.488 20.480 22.829 22.949 24.097 20.456 19.935 18.721 22.287 23.476 21.742 22.509 22..383 23.628 24.600 23.665 24.792 24.875 25.552 23.636 26.043 27.139 25.926 27.117 22.029 26.864 26.369 24.828 27.772 25.965 25.455 25.274 4.088 4.523 5.426 5.426 5.100 5.100 6.473 8.319 9.670 9.670 6.676 6.676 6.676 6.770 7.058 8.538 6.676 6.770 7.058 8.538 8.538 8.538 8.538 8.538 8.538 8.538 8.538 8.538 8.538 8.538 8.538 8.548 8.558 5.069 5.159 4.316 3.167 2.978 2.885 6.327 7.089 8.440 8.422 9.127 7.1286 6.399 4.442 4.897 4.899 4.829 3.444 3.498 449 448 448 451 451 451 451 451 569 570 571 

27.287 27.640 26.662 27.070 27.164 27.425 27.425 27.581 27.820 27.820 27.820 27.820 27.820 27.820 29.867 29.867 29.867 29.867 29.867 29.867 29.867 29.867 30.665 30.665 30.665 30.884 30.330 29.835 29.107 28.853 28.853 29.328 31.709 3.895 3.642 8.77 9.942 10.062 10. 9.821 110.339 111.061 111.061 112.868 113.402 112.868 113.402 110.675 

2.66 3.65 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 3.37 2.00 3.37 3.37 3.62 4.85 4.85 4.85 3.37 3.62 3.37 3.62 4.85 5.88 8.85 6.85 32.717 33.552 32.430 33.043 33.043 33.043 33.049 36.329 36.329 36.329 36.329 36.329 36.329 36.329 36.329 36.329 36.329 36.329 37.624 38.168 36.329 36.329 36.329 36.329 37.624 38.768 38.7788 38.7788 38.7 37.641 37.767 38.821 38.604 4.511 4.238 8.218 9.459 111.027 10.941 6.866 7.094 6.297 6.296 6.296 6.297 6.296 6.297 6.296 6.297 7.094 7.094 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.296 6.296 7.096 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.296 6.296 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.296 6.297 6.297 6.297 6.296 6.297 6.318 6.3 13.432 14.296 13.107 13.752 13.250 13.849 13.120 13.454 14.312 12.217 11.796 12.237 12.297 12.297 12.297 12.297 12.297 12.368 13.252 13.758 14.736 15.297 17.361 460 460 460 461 461 GLU A
GLU A
GLU A
SER A
MET A VALL
WALL
WET
MET
MET
MET
MET
MET
MET
GELU
GELU
GELU
GELU 

15.00 13.58 17.87 12.54 15.03 13.80 16.34 18.04 17.67 21.39 24.00 20.75 18.80 18.58 21.36 23.94 24.78 000.00 000000 1.00 000000 39.926 41.321 40.359 42.729 43.440 44.428 45.889 46.085 47.260 45.086 45.554 45.356 46.399 40.192 42.533 39.072 39.244 39.965 41.985 40.987 40.971 38.654 45.376 45.467 11.195 11.628 46.301 6.641 6.619 7.176 7.574 2.995 2.288 1.391 3.837 5.984 6.526 6.271 8.538 8.543 6.218 .479 4.958 6.912 6.509 8.192 3.978 2.740 .852 .509 .330 .384 5.767 8.431 16.491 17.684 18.055 19.089 19.089 19.070 20.196 20.352 21.027 22.427 22.427 22.561 23.388 20.064 21.057 118.835 119.056 110.0 14.653 13.464 12.086 10.931 9.546 8.469 15.886 16.346 18.981 19.486 18.818 19.154 18.257 697 698 699 700 701 683 6844 6855 687 687 689 690 690 693 693 

23.40 23.39 19.92 25.54 24.22 23.40 24.26 23.45 24.43 25.52 26.28 24.93 26.91 26.91 28.46 26.91 25.86 26.46 27.70 28.15 25.97 25.84 23.67 26.30 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1111 1.00 1.00 41.616 40.982 41.027 45.573 45.988 45.572 45.983 44.801 43.581 42.390 43.836 47.087 47.427 48.310 49.621 50.339 47.500 46.285 48.091 46.458 47.112 46.636 46.260 45,210 44.944 45.661 46.174 45.835 46.723 48.845 47.218 18.043 4.516 8.580 5.089 5.467 5.979 8.862 8.357 9.644 10.774 11.941 12.106 13.245 13.426 10.760 12.313 12.878 12.086 11.815 2.894 13.383 13.000 12.376 25.481 27.641 23.560 24.669 23.067 23.174 23.753 21.940 21.160 26.015 26.367 23.871 24.393 26.380 21.893 22.034 21.022 21.227 20.666 20.567 21.907 22.706 24.921 18.600 17.516 24.13721.697 15.514 24.092 19.406 19.196 6.221 468 468 467 467 467 467 468 468 468 468 468 469 469 469 469 469 469 470 467 ARG
ARG
ARG
ARG
ARG
ARG
LEU
LEU
LEU
LEU LEUU LEUU LEUU LEUU SER SER SER SER SER SER SER TILE TILE ILE ILE ILE GLN GLIN GLIN GLIN GLIN ATOM ATOM

8.01 10.92 13.01 15.68 13.49 14.53 13.72 12.47 12.77 13.73 13.11 1.000 1.00 1.00 1.00 41.900 39.175 40.810 38.527 37.360 38.897 39.954 37.936 36.691 35.597 41.031 38.604 37.894 36.867 11.329 15.623 15.264 16.910 13.278 12.095 20.550 17.877 18.062 17.578 17.435 17.204 17.204 17.332 12.879 18.016 18.006 16.436 19.379 15.223 19.295 18.603 19.726 20.648 19.095 20.444 19.944 20.018 119.930 19.840 20.136 19.705 20.705 20.221 21.978 22.878 25.288 26.724 27.400 22.467 22.438 22.188 21.832 21.567 21.072 21.999 474 474 475 475 475 ASN ASN ASN ASN ASN
PHE
PHE
PHE
PHE
PHE
PHE
PHE
PHE
PHE PHE LEU LEU LEU LEU LEU LEU 

30.562 29.680 30.461 29.360 29.755 28.706 27.511 28.984 34.367 32.794 32.164 32.784 31.877 32.539 33.419 28.146 28.165 27.063 25.841 24.799 22.488 23.620 25.332 23.540 24.829 14.102 12.908 16.520 20.849 17.098 16.766 17.310 18.257 19.127 15.086 16.762 17.835 17.630 13.726 15.051 20.037 20.712 21.572 22.520 23.519 20.791 20.205 20.198 20.198 20.198 20.198 20.198 17.615 20:057 19.612 21.812 478 478 478 479 478 478 

21.275 21.607 14.590 11.610 10.899 12.066 11.733 12.555 13.127 14.107 15.586 10.264 9.590 9.758 8.378 8.378 8.323 7.382 6.323 7.753 7.415 20.218 20.616 19.779 18.140 18.986 19.379 18.721 17.323 16.500 16.343 15.629 17.220 17.220 17.220 17.220 17.220 17.220 17.220 18.163 19.135 19.135 19.135 19.135 19.135 19.231 19.231 19.232 110.233 1 HIS A HIS A HIS A HIS A HIS A MET A PHE PHE PHE HIS HIS HIS HIS HIS HIS HIS 

10.36 12.45 17.37 14.99 1.00 00.1 1.00 22.588 23.837 20.140 21.092 22.198 24.279 22.729 22.163 22.406 21.395 20.441 23.462 23.673 24.604 18.984 19.332 18.485 19.661 19.324 6.081 3.023 2.829 3.780 2.669 1.779 5.885 7.153 5.660 1.614 5.903 6.192 3.885 4.496 2.513 1.438 3.330 2.178 0.850 0.864 1.468 0.480 6.983 3.233 .3.472 0.371 0.631 13.503 12.815 12.700 11.860 12.957 12.237 12.343 11.536 10.047 16.993 17.122 17.998 18.230 15.738 15.444 14.888 13.887 15.873 16.299 17.695 16.341 15.806 12.851 14.109 491 491 491 491 491 491 CYS A ALA A LEU A GLU A ALA A
ALA A
CYS A
CYS A
CYS A
CYS A
CYS A LEU ALA ALA ALA 905 906 907 904 908 

12.13 18.39 18.74 23.19 23.00 22.03 24.64 27.98 27.33 29.40 16.42 21.16 20.54 33.44 ..00 1.00 00: 1.00 00. 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 20.293 19.610 21.852 17.742 15.531 15.544 14.534 12.891 14.935 16.687 17.755 16.778 18.009 15.922 17.836 18.968 L6.884 14.927 14.984 0.337 -1.038 2.329 -1.000 .2.219 0.035 1.316 -2,438 -2.968 -2.993 -4.310 -5.344 -5.210 -6.267 -6.220 -4.776 -5.593 -4.693 -4.623 5.221 -5.942 -6,334 5.204 -4.042 -3.904 8.558 9.550 12.173 14.608 11.802 11.449 11.016 8.838 9.637 10.363 11.314 10.911 10.876 8.754 10.344 10.405 10.586 11.688 12.290 13.319 10.445 11.097 11.219 7.876 8.657 11.094 495 496 496 497 Ä VAL VAL VAL VAL VAL 919 920 921 922 923 924 925 940 941 942 945 947 ATOM ATOM ATOM ATOM ATOM ATOM ATOM ATOM ATÓM ATOM ATOM ATOM

2	了.

<u>:</u> .

																		•																							
· c	) Z	. ບ	ນ.	0	ບ	0	Z	.ບ	ບ	ບ	ບ	Z	ບ	z	N	ບ	0	×	ບ	บ	0	บ	0	Z	ບ	ບ	0	ບ	0	N	ບ	ບ	0	N	บ	ບ	0	ט	ບ	<b>O</b>	z
10.64		43.56	43.58	11.96	45.17	15.09	46.76	18.01	17.71	19.22	50.50	52.41	52.33	19.40	19.92	18.87	18.55	49.79	50.64	50.82	51.88	6.0	50.85	57.14	7	ᅼ.	2	55.73	56.00	54.44	ο.	51.71	51.34	50.64	49.39	50.13	49.53	19.41	48.11	48.23	Ö
1.00	1.00.1	1.00		1.00	1.00	1.00	1.00	1.00 4	1.00	1.00	1.00	1.00		1.00 4	1.00	1.00	1.00 4	-	1.00	1.00			1.00	1.00				1.00	1.00	1.00		1.00	1.00	1.00	1.00 4	1.00	1.00 4	1.00 4	1.00 4	1.00 4	1.00 4
12, 563	.47	.20	12.338	.95	.08	9.973	.37	.40	10.797	.63	.91	0.02		9.976	10.132	10.321	48	.09	99	.02	.89	. 58	.98	.28	0.420	.21	.21	.47	0.559	.43	0.499	1.851	•	2.179	.45	. 42	4.774	•	4.674	4.691	.71
V	-5.887	-5.935	-6.704	-5.924	•	-5.993	-7.631	.29	-9.738	-10.619	-11.420	-10.547	•	-12.270	•	-7.563	-8.171		-5.356	•	-3.328	-4.738	-4.752	1.112	0.166	-1.239	-1.704	0.689	-0.084	2.013	2.644	2.435	.40	1.160	0.702	•	0.219	1.834	4.	2.708	۲.
	9.233	•	•	ĸi.	•	•	•	•	7.233	.773	.473		•	•	•	•	5.050	•	5.058	5.166	4.077	4.924	3.844	9.297	10.177	ö	8.726	1.6	2.60	H	3.07	13.712		13.924	4.49	.03	.48	16.783	14.164	14.292	.77
4	499	499	49	4	499						500						500								508					509		509			510	510	510		510		
TYR A	•	SER A	SER A	•	SER A	SER A	ARG A	ARG A	ARG A	ARG A	ARG A		ARG A	ARG A	ARG' A	ARG A	ARG A	SER A	SER A	SER A	SER A	SER A	SER A	SER A	SER A		SER A	-		GLY A	•	GLY A	GLY A	THR A	THR A	THR A	THR A	THR A	THR A	THR A	
c	) Z	ð	8	90	ບ	0	z	ð	පි	පි	8	NE	CZ	NHI	NH2	ບ	0	z	g	8	g	บ	0	z	ð	B	8	ບ	0	z	ජ	ບ	0	N	đ	GB	091	CG2	บ	0	z
961	962	963	964	965	996	296	968	696	970	971	972	973	974	975	916	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	966	997	998	666	1000	1001	1002
ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	. ATOM	ATOM	ATOM .	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	. ATOM	. ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	. ATOM	ATOM

2

:'

. . . .

														•																										
4. 1		; ;	ω.	٠:	2.6		7.3	9.	8.	9.6	9.2	8.	4.3	2.3	7.0	0.7	4.0	4	5.2	3.0	9.6	œ	3.5	_	φ	Q	9	'n	σ	1.9	æ	3.0	.7	7.		11.10	1.5	0	6.57	3
	1.00 1.00	• •	٥.	°.	۰.	0.	0.	°		0.	0.	0	1.00	1.00	1.00	1.00	1.00	1.00	0.	0	1.00	0.	°.	°.	1.00	1.00	0	1.00	°	°	°.	٥.	0.	1.00	1.00	1.00	1.00	1.00	1.00	1.00
01 1		. 0	. 74	9	.82	.32	.49	1.72	3.09	3.42	.27	0.27	.22	.29	1.34	.93	.25	2.15	1.62	3.46	4.4	4.93	5.6	5.46	5.12	7.0	17.219	5	3.88	4.19	3.07	2.67		1.16	40	2.1	49	1.5	10.997	0.4
0 (	. 4	. 70	.69	.01	.71	00.	.76	Ŋ,	4.	9.	'n	ĕ.	ö	9.	35.	96.	8	-0.743	.03	.92	.17	.9	03	.13	.67	.63	1.743	9.	97.	. 20	.18	.46	.05	. 79	90.	.49	.69	.09	4.084	ų.
D. T	• •	1.71	. 55	4.4	5.6	3.9	4.7	9.	4.5	5.0	5.6	5.74	5.76	6.54	7.59	8.13	7.24	8.59	9.36	8.53	9.33	0.45	1.41	2.77	3.60	3.07	21.715	0.89	9.83	9.17	0.91	1.49	2.50	2.04	1.58	0.44	.67	9.35	3.37	7.11
ASP A 511	A 51	A 51	A 51	A 51	A 51	51	A 51	ហ	A 5.	A 5.	A S	A 5	A 53	A 51	A 51	A 51	A 51	A 51	A 51	A 51	A 51	A 51	A 51	A 51	A 51	A 51	ø	A 51	A 51	7.	A 51	A 51	A 51	A 51	A 51	A 51	0 A 51	P A 51	P A 51	TRP A 516
<b>5</b> 8	9 පි	OD1	002	ບ	0	Z	ð	B	b D	CDI	CD2	บ	0	z	ð	g	ე ე	ບ	ọ	z	ð	CB	CG	CDI	CE1	CZ	CE2	97	ບ	0	z	S S	B	S S	8	บ	0	z	S S	B
1003	00	1006	00	8	8	01	01	1012	01	_	01	01	0	01	0	02	02	1022	02	02	.0	0	02	0	1029	03	1031	03	03	9	ന	03	03	03	03	<#	9	1042	<#1	eH.
ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM

ט	ບ	z	ט	ט	ט	ט	ບ	ນ ,	ט	0	×	บ	ບ	ט	บ	ט	ບ	0	×	ับ	ບ	ບ	ט	ບ	ซ	0	×	ບ	บ	ซ	0	×	ບ	0	Z	บ	ບ	ບ	ບ	ซ	o	i
6.53	Η.	٥.	2.00	ω.	0	0	2.00		4		τί	Ξ.	n)		٥.	0.	۳.	ຕຸ	ຕຸ	o,	ന	ო.	'n	٥.	7	ι.	9.38	ᅥ	3.7	3.0	9.0	Ø	4.0	1.3	ᆏ	Ŋ	4.0	10.55	3.7	o,	~	
0	0	0	1.00	0	0.	0.	0	1:00	•		1.00	1.00	0	1.00	1.00	1.00	•	1.00	0.	0	1.00	0	0.	•	.0		0.	0	00.	00.	00.	00.	00.	00.	0.	•	00.	00	00.	•	0	
	.53	.28	35	0.33	.55	1.74	0	.56	2	1.70	3.20	4.26	5.54	6.49	5.85	25	4.58	5.01	4.37	4.73	4.63	5.62	5.64	5.97	3.81	4.26	12.511	1.52	0.16	0	Н	Н	7.	1.7	1.8	2.0	4.	N	1.2	Н	3.0	
.31	.93	99.	.56	.73	.52	.08	ω.	16	16	35	74	58	73	44	16	32	9		31	27	67	52	12	83	43	52	8.196	$^{\circ}$	Ŋ	4	-	0.0	0.0	1.2	ന	0	g	9.580	Н	11.115	. 19	
6.10	6.19	5.05	4.	4.86	4.21	2.97	12.376	ω.	7.	7.92	7.66	7	ง		4.		œ.	۲.	ď	。	$\dot{\mathbf{H}}$	ď	ю М	÷.	ö	ö	20.409	ö		÷.	ö		9.04	9.00	7.94	70	5.62	14.333	31	7	16	
A 51	TRP A 516	ď	ø	Ø	Ą	ø	ø	Ø	ø	ILE A 517	ď	ø	ø	ø	ø	Ø	Ø	Ą	ø	ø	ASN A 519	ď	ø	ď	ø	Ø	ø	Ø	¥	A		Ø	Ā	Ą		ı.						
ဗ္ဗ	9	NET	CEZ	CD2	CE3	CZ3	CH2	CZ2	ט	0	z	S S	8	CG1	9	CG2	ບ	0	Z	CA	CB	ည	CD1	CDS	บ	0	z	ð	CB	ပ ပြ	001	ND2	บ	0	Z	ð	8	CG1	CG2	ט	0	
0	d	04	1048	04	05	0.5	1052	05	1054	0.5	1056	05	1058	1059	1060	1061	1062	1063	1064	1065	1066	1067	1068	1069	1070	1071	1072	1073	1074	1075	1076	1077	1078	1079	1080	1081	1082	0	80		08	•
ATOM	, ATOM	ATOM	ATOM		ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM		. ATOM		ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM		ATOM	ATOM	. ATOM	ATOM	· ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	٠						

19.629 19.873 19.828 17.090 14.599 15.287 14.661 16.571 12.771 13.624 11.539 11.082 10.220 9.986 8.528 8.528 9.957 10.191 9.219 10.461 9.601 11.724 11.724 11.724 11.724 11.724 11.724 11.724 11.724 11.724 11.724 11.724 LIEU A
LIEU A
LIEU A
LIEU A
LIEU A
LIEU A
ASN A
ASN A
ASN A
ASN A
ASN A
ASN A
LIEU A
L 1089 1090 1090 1090 1090 1095 1095 1096 1099 1100 11100 11100 11100 11100 11100 11100 11110 1115 

23.150 24.286 22.136 22.227 20.803 20.713 20.311 20.164 20.441 20.784 20.917 23.126 24.986 26.088 22.816 23.562 23.011 24.090 26.287 27.345 10.775 10.941 11.619 7.375 7.280 6.649 1.668 1.711 2.858 2.977 3.915 3.849 3.312 31.814 32.505 31.823 31.822 31.822 31.822 32.494 32.409 24.739 24.739 24.739 24.739 24.739 24.739 24.739 24.739 24.739 25.208 26.598 27.251 27.251 27.251 27.251 27.251 27.387 27.387 27.387 27.387 27.387 5239 5239 5329 ASP A PHE A TYR A PHE PHE PHE PHE ASP ASP ASP 1132 11134 11135 11136 11137 11139 11140 11141 11142 11144 11145 11146 1149 1149 1150 1151 1152 1153 1154 1155 1156 1156 1157 1159 1160 191 

4.4.7.6.00 4.56.00 4.56.00 4.56.00 4.55.00 4.55.00 4.55.00 4.6.68 4.6.60 4.272 4.052 4.971 4.227 6.035 2.598 2.598 1.762 0.353 0.353 -0.133 -1.674 -0.5111 -1.055 -1.055 -2.845 -2.828 -1.098 -1.098 28.593
27.983
28.524
28.524
28.930
24.930
23.871
22.577
21.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
22.123
23.123 LYS A CLYS A CALL A CALL A CALL A CLUC A CLU 11171 1172 1173 1174 1176 1176 1177 1178 1179 1180 1181 1181 1181 1183 11186 11186 11187 11188 11188 11190 11193 11194 11196 11199 11199 11200 

7.13 7.81 8.38 11.82 20.54 26.43 26.23 6.91 7.82 6.92 7.45 6.81 6.81 7.71 7.71 14.92 14.92 11.46 2.46 4.126.38 6.33 7.70 8.69 10.13 8.45 5.49 10.15 8.74 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 ..00 L.00 1.00 L.00 1.00 1.00 1.00 30.165 30,621 29.670 27.637 31.638 31.910 34.010 34.920 34.638 35.588 35.157 34.540 35.570 30.160 32.571 33.897 34.626 28.161 36.319 33.873 34.370 33.966 32.870 30.821 30.261 -1.477 -1.305 -2.296 -2.885 -3.360 -2.886 -2.777 -2.945 -2.665 -3.015 -3.082 -3.503 0.503 -1.537 -2.681 -3.034 -2.643 2.954 -1.626 -0.901 -1.404 3.560 -4.373 -5.145 -6.240 -4.820 16.430 18.138 17.052 17.956 18.874 19.245 20.210 21.589 20.014 19.039 24.072 25.029 17.853 17.360 22,582 17.402 16.250 14.926 14.879 13.550 12.180 11.089 10.984 20.02 21.367 19.894 .8.664 6.297 13,655 10.377 537 537 537 537 537 539 539 539 539 539 539 539 539 539 539 539 539 539 537 LIYS A SILYS A SILYS A SILYS A SILYS A SILYS A SILYS A SILY A SILA A SIL GLU A GLU A GLU A GLY A TE LYS GLY GLY GLY CONTRACTOR 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 ATOM ATOM

7.19 9.69 9.66 10.93 11.59 11.59 14.78 14.78 23.09 17.48 11.05 10.33 11.63 13.95 8.14 7.80 6.70 4.89 21.85 .00 00.1 1.00 11.00 1.00 1.00 1.00 32.421 32.607 33.346 29.706 29.706 27.941 27.941 27.973 28.095 27.769 26.759 26.759 26.759 24.831 25.939 25.690 25.540 25.014 24.853 24.106 21.819 23.932 25.167 34.413 33.074 23.167 -4.668 -4.622 -7.378 -7.373 -5.179 -10.196 -10.139 -12.283 -9.615 -10.978-6,684 -10.650 -11.004 -16,618 -17.233-11.979 8.315 8.603 10.911 10.911 10.126 112.207 114.075 114.095 115.492 115.492 117.403 117.852 117.852 117.852 15.657 15.645 12.469 10.487 14.089 14.325 16.929 16.848 15.749 15.186 14.967 14.719 15.747 17.262 6.117 GLU 1292 1293 1294 1291 

19.54 29.26 21.36 8.48 10.12 5.86 8.87 00.1 1.00 00.1 1.00 00:1 . 00 00: ..00 .: 00 ..00 ..00 00. 1.00 22.867 27.190 23.875 23.585 23.224 22.157 22.053 23.487 21.088 20.627 20.689 19.629 18.172 16.932 16.253 17.003 18.206 19.357 21.366 21.962 23.369 26.159 21.439 24.923 26.827 21.580 24.469 19.213 20.09 33.396 24.820 -8.632 -6.831 -8.475 -8.603 -8.402 -9.080 -10.106 -8.235 -9.481 -8.952 -7.911 -9.683 -12.366 -13.592-13.189 -14.338 -9.024 -7.426 -7.050 -4.725 -5.673 20.060 19.527 18.601. 17.582 17.608 19.986 19.203 20.646 17.703 18.459 20.837 21.254 21.477 19.100 18.258 19.919 19.698 18.083 17.394 20.432 20.211 21,321 19.118 18.486 17.121 19.851 546 548 547 547 548 548 548 548 548 548 548 548 549 549 549 549 547 547 547 547 547 TIE ILE ILE ILE LYS LYS HIS LYS LYS LYS LYS LYS LLYS HIS HIS HIS HIS HIS LEU LEU LEU 1298 1299 1300 1301 1302 1303 1297 1305 1306 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1328 1329 1332 1333 1335 1336 1331 ATOM ATOM

1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 ..00 18.076 18.243 18.736 20.180 20.905 18.435 25.602 18.496 18.971 -6.849 -6.750 -5.935 .10.655 -7.403 -8.435 -5.292 -2.972 -2.146 -2.480 -1.706 -2.959 -2.557 -4.381 -2.999 -8.372 -7.818 -7.851 -3.111 -2.034 25.734 27.060 27.664 27.773 24.352 25.304 23.467 23.615 22.387 20.754 24.890 25.704 25.084 26.265 26.211 27.140 26.917 26.704 26.930 27.576 1348 1349 1350 1351 1352 1353 1353 1355 1356 1356 1358 1359 1360 1364 1364 1365 1366 1367 1377 1377 1375 1375 1375 1375 1375 ATOM ATOM ATOM ATOM ATOM

12.35 12.81 19.23 22.82 25.22 23.17 23.51 5.89 2.19 5.06 3.84 6.34 7.02 14.43 3.43 2.79 3.49 6.19 13.37 9.46 1.00 000.11.0000.11.000.11.000.11.000.11.000.11.0000.11.0000.11.0000.11.0000.11.0000.11.0000.11.0000.11.0000.11.0000.11.0000.11.0000.11.0000. 1.00 1.00 1.00 1.00 1.00 .00 1.00 1.00 1.00 ..00 1.00 . 00 1.00 1.00 1.00 1.00 1.00 1.00 15.910 13.043 16.218 15.400 18.578 14.251 17.777 18.957 19.538 17.040 15.983 14.419 13.647 11.619 18.067 17.582 19.214 22.900 13.825 15.032 18.862 20.277 22.556 17.404 21.619 18.054 15.017 .8.091 -1.417 0.438 1.516 -4.376 -4.086 -4.276 0.966 2.324 0.279 1.023 -1.673 -2.102 -2.609 -0.835 -0.890 2.949 .3.923 -4.665 -5.820 -1.514 -0.732-1.072-2.170-1.284 -1.515 -1.491 -3.807-3.495 26,830 25.422 24.910 23.632 22.735 23.255 28.790 28.975 28.195 26.718 28.762 31.301 32.137 32.147 31.501 32.417 29.447 25.860 30.462 30.774 31.502 30.101 33.009 33.269 32.673 31.360 33.642 28.480 34.222 30.780 557 557 557 557 557 558 558 558 558 558 558 558 558 558 559 559 559 559 559 557 557 ARG ARG ILE ILE ILE ILE ILE MET MET MET MET MET MET MET GLU ARG ARG ARG ILE ILE IJE GLU GLU GLU GLU NH2 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1382 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1412 1413 1414 1415 1416 1411 1417 418 1419 1420 ATOM ATOM

17.354 18.810 16.884 17.530 15.806 15.316 15.316 15.308 2.881 1.796 1.908 2.948 3.804 2.32 2.019 1.785 2.524 2.524 4.193 3.756 4.693 4.095 5.109 5.921 4.535 4.535 4.693 4.095 5.921 7.923 7.777 5.825 6.044 6.253 7.145 6.068 6.356 5.550 8.532 8.918 1.694 32.339 33.008 30.020 30.323 28.333 27.969 27.969 27.969 31.326 31.326 33.259 33.863 33.259 33.259 33.259 33.259 33.259 33.259 33.259 33.259 33.259 33.259 33.259 33.259 34.269 35.073 36.036 37.252 5500 5000 1432 1433 1434 1435 1436 1437 1438 1439 1440 1442 1443 1448 1449 1451 1451 1452 1453 1455 1455 1455 1456 1457 1458 1441 1446 1447 

14.835 15.365 16.678 16.678 16.709 17.982 17.875 17.867 20.083 20.031 18.927 20.031 20.393 21.382 20.393 21.383 20.393 21.383 19.739 19.528 20.895 10.766 11.762 12.257 10.892 10.379 8.890 8.341 11.423 12.087 12.119 12.026 11.141 11.300 11.860 9.997 9.185 7.839 6.643 7.041 9.780 9.766 10.317 10.808 11.136 9.923 8.914 7.757 7.573 8.556 9.719 11.092 33.058
32.118
30.751
30.751
30.751
30.719
31.929
31.929
32.472
32.849
32.752
33.922
34.778
33.922
34.778
33.922
34.778
35.953
36.652
36.514
36.523
36.523
37.338
36.523
37.338 ASP A ASP A SER A PRO A PRO A PRO A PRO A LEU A PHE A 14473 14473 11474 11476 11477 11480 11483 11483 11483 11488 11488 11488 11488 11488 11488 11488 11488 11488 1467 1468 1469 1470 1471 1492 1493 1495 1496 1497 1498 1499 1502 1494

21.52 21.46 23.88 15.22 15.07 15.55 14.55 12.31 12.90 17.30 18.35 18.15 16.97 15.24 15.89 17.39 6.14 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 23.447 24.705 24.800 26.233 27.185 26.291 24.850 25.954 23.745 23.850 22.628 23.290 22.098 21.114 22.425 23.983 22.296 20.020 25.401 25.224 10.621 10.127 11.348 9.247 10.761 10.761 7.746 6.981 8.825 11.088 10.949 12.192 13.190 14.242 15.079 11.657 17.213 13.802 36.747 35.738 37.892 37.838 38.703 37.023 36.028 35.809 35.722 34.536 38.461 38.945 39.068
40.376
40.645
39.959
39.857
42.098
41.435
42.272
42.087
44.287
44.287
44.287
44.287
44.287 40.876 39.394 39.020 37.544 36.639 37.315 571 572 572 572 572 572 572 572 572 ASP ASP A BLEU A ASP ASP ASP 

12.64 10.72 8.91 36.86 13.34 13.52 17.99 9.09 12.87 33.03 38.84 41.17 42.67 12.17 8.17 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 28.946 27.028 24.390 24.601 26.785 25.685 33.813 30.153 33.190 34.033 29.633 11.424 12.565 13.534 14.659 16.006 16.280 11.566 11.456 12.556 14.554 9.547 9.648 6.982 7.546 6.265 6.374 9.097 6.691 15.800 16.976 9.256 6.834 7.811 5.785 4.625 6.460 7.758 6.694 46.462 45.820 46.552 45.949 46.096 47.060 45.279 46.556 47.095 46.930 36.636 35.896 36.738 35.927 35.367 34.293 33.630 32.625 31.728 33.274 33.531 32.676 576 577 577 577 577 577 577 578 578 578 578 578 644 644 щщ щ щщ 開開 SER SER SER 1549 1550 1551 1552 1553 1554 1555 1556 1558 1559 1550 1560 1560 1563 1564 1565 1566 1567 1568 1569 1573 1574 1575 1576 1577 1578 1580 1582 1583 1585 1587 1588 1589 1581 1584 1586 1590 ATOM ATOM ATOM ATOM

 6
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 30.294 30.609 29.371 28.646 4.459
3.1919
3.1919
3.1919
3.1919
3.1919
3.31919
0.0540
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0.0916
0. 36.846 38.046 36.046 36.3327 36.3327 36.3327 36.3327 36.3327 36.3327 36.3327 36.3327 36.3327 37.741 6647 6477 6477 6477 6477 6477 6478 1630 1631 1632 1633 

3.86 5.25 9.94 9.85 111.02 111.02 111.02 111.02 111.02 111.02 112.73 113.88 113.88 1.000 0.000 26.566 26.388 23.240 25.177 28.518 28.071 24.665 24.528 22.068 -1.175 -4.552 .2.803 4.068 5.204 -3.033 -3.311 2.320 -5.204 -4.016 -4.433 5.454 -3.656 1.858 34.039 32.592 31.683 36.103 34.602 34.713 35.971 36.417 34.803 30.444 29.457 29.069 34.665 34.680 35.172 35.796 36.340 37.138 35.261 36.923 37.162 37.606 38.644 39.505 653 653 653 653 654 654 654 654 654 654 654 653 653 653 щ LYS LYS LYS LYS LYS LYS LYS 1639 1640 1641 1642 1648 1649 1650 1651 1652 1653 1655 1656 1657 1658 1659 1660 1661 1643 1644 1645 1646 1647 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 1675 

6.67 6.08 7.27 7.68 9.00 8.43 8.28 8.68 8.59 8.85 111.54 14.10 10.91 12.41 11.29 8.10 7.91 8.11 8.99 24.006 23.612 20.884 19.981 20.924 20.556 20.658 24.491 24.087 19.460 -6.470 -14.579 -7.943 -9.615 -8.820 -9.905 -7.045 -12.435 -8.824 -9.422 -10.196 -10.806 -13.629 -13.070-12.090 -13.017 -12.-143 31.217 32.021 36.008 39.143 39.850 40.177 40.775 42.608 41.822 42.353 40.511 39.996 39.053 39.591 36.360 35.272 33.118 32.700 36.009 36.065 37.004 38.156 39.093 34.794 34.122 32.951 38.893 39.271 37.773 36.976 658 658 658 659 659 659 659 659 659 659 629 629 6557 6577 6577 6577 6577 629 660 660 660 ARG LEU LEU LEU LEU LEU LEU 

3.60 3.87 2.00 12.78 13.10 13.72 9.20 15,28 15.36 14.40 15.63 15.58 16.02 9.15 15.24 15.75 16.03 18.60 12,83 15.89 15.40 15.75 16.31 15.92 17.99 18.03 14.11 1.00 16.053 .6.330 18.096 17.273 18.462 19.265 18.918 17.630 18.904 20.082 20.666 22.090 18.396 17.986 16.740 16.467 18.735 20.086 19.771 14.515 18.206 22.606 22.388 .9.840 19.225 17.271 23.284 9.145 17.126 6.472 5.290 3.840 -8.468 -12.879 -13.230 -14.658 -15.448 -12.854 -16.268 -18.274 -18.320 -17.296 -18.403 -16.930 -17.868 -17.267 -16.882 -18.315 -17.463 -16.291-19.335 -17.208 -15.473-14.082 -18.201 -16.17132.973 33.784 38.478 40.902 41.803 40.656 40.287 41.057 40.453 39.508 41.900 38.625 43.286 44.132 43.829 41.198 40.829 40.059 31.652 38.985 40.143 39.030 40.700 40.592 38.274 36.934 36.179 36.076 39.059 39.092 39.661 661 661 661 661 662 662 662 662 662 662 662 662 663 663 663 663 663 663 663 663 664 664 664 664 665 665 LLEU ASN ASN ASN ASN ASN ASN ASN THR THR ARG ARG LEÜ LEU LEU LEU LEU LEU 開開 THR LEU LEU LEU LEU LEU LEU LEU 1727 1728 1729 1729 1730 1731 1732 1734 1735 1736 1737 1738 1739 1739 1724 1725 1726 1745 1746 1747 1742 1743 1744 1748 1749 1750 1755 1751 1752 1753 ATOM ATOM

17.77 18.28 12.51 23.37 22.67 20.39 20.67 18.34 18.39 19.07 20.80 17.26 18.42 18.63 19.29 20.70 17.97 18.41 19.53 15.39 18.65 18.31 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1,00 1.00 1.00 18.192 17.678 17.430 17.260 18.009 18.478 19.536 20.048 21.526 21.937 22,277 16.166 14.616 13.896 16.035 13.950 17.291 17.387 15.127 13.988 15.341 13.001 12.412 10.861 10.606 13.553 12.850 15.012 15.484 13.122 15.382 15.762 15.007 13.477 14.819 -20.191 -21.576 -21.680 -23.085 -21.419 -22.126 -22.508 -23.691 -21.979 -21.630 -20.771 -22.369 -21.858 -21.407 -19.999 -22.131-21.891-22.719 -23.613-19.874 -21.649 41.558 41.330 40.404 39.851 38.775 36.292 35.058 34.778 42.273 42.257 40.005 34.094 42.450 42.651 43.206 44.601 43.433 43.167 46.559 45.892 47.206 42.463 41.170 40.892 40.586 42.019 45.677 47.828 48.413 44.255 42.191 48.698 667 667 667 667 667 667 667 668 668 668 668 668 668 668 668 668 668 668 668 699 669 699 699 699 699 670 670 670 670 дд **мимимимимимими** CYS CYS GLU GLU GLU GLU GLU GLU GLU 1764 1765 1766 1766 1769 1770 1771 1772 1772 1773 1773 1774 1775 1778 1780 1780 1781 1782 1783 1784 1786 1786 1788 1789 1790 1791 1792 1794 1794 1796 1796 1797 1798 1799 1799 1777 

Z U U U U O O U O Z U U 24.39 23.25 23.92 25.13 21.86 20.75 19.61 19.92 34.47 19.13 20.60 18.47 18.13 18.19 19.76 18.97 1.00 16.227 17.765 8.858 16.644 16.637 15.221 12.787 17.431 18.226 17.308 15.737 14.413 18.006 17.439 19.131 14.267 16.035 14.874 13.920 19.255 20.274 21.309 22.379 21.623 21.088 21.901 21.773 -26.667 -27.605 -23.548 -21.670 -22.309 -22.947 -22,506 -20.630 -19.848-21.811 -21.913 -23.021 -20.396 50.113 51.058 48.806 49.983 51.097 52.507 49,540 49.369 52.234 54.075 49.579 48.081 50.715 50.420 52.982 52.909 50.723 50.867 54.142 50.904 50.422 49.687 50.691 50.126 672 673 673 674 674 674 674 674 674 675 675 675 675 675 675 щ щ ф GLU GLU GLU HIS HIS HIS HIS HIS HIS HIS PRO PRO PRO PRO PRO PRO GLU GLU GLU GLU GLU GLU GLU LEU OE2 CG CE1 CD2 OE2 1807 1808 1809 1810 1812 1813 1814 1815 1816 1818 1820 1811 1,821 1822 1823 1825 1826 1827 1828 1828 1830 1831 1824 1832 1833 1834 1835 1836 1837 1838 1839 1840

ATOM

ATOM

ATOM ATOM ATOM

ATOM ATOM ATOM ATOM

ATOM ATOM

ATOM ATOM ATOM ATOM

UUUUU SOUUUUU SOUUUU SOOOUUUU SOOO

14.03 12.86 14.72 17.27 15.74 16.88 13.75 14.06 13.20 14.08 16.75 18.50 17.30 16.02 15.51 13.46 13.27 13.66 13.87 14.37 15.38 11.31 13.66 12.95 12.55 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 11.000.11.0000.11.000.11.000.11.000.11.000.11.0000.11.0000.11.0000.11.000.11.0000.11.0000.11.0000.11.0000.11.0000.11.0000.11.0000.11.0000.11.0 17.348 15.866 17.566 19.905 19.703 20.830 21.396 21.847 22.666 22.098 23.901 21.749 21.520 22.788 23.765 25.031 26.257 26.386 27.580 28.220 27.418 23.184 23.578 22.248 21.623 20.884 21.826 21.105 20.210 20.652 19.860 20.660 17.076 -15.636 -16.503 -16.590 -12.439 -13.393 -12.585 -11.445 -11.903 -12.548 -13.349 -11.020 -16.530 -15.737-13.318 -13.422 -12.466 -11.675 -10.987 -12.008 -13.950 -11.481 -12.924 52.243 52.008 53.405 49.986 50.038 46.618 45.378 44.387 43.557 47.589 48.062 49.142 49.775 48.698 50.306 49.895 50.907 51.758 52.940 53.840 54.959 53.795 47.758 44.427 49.162 48.355 48.616 51.018 49.611 50.914 50.072 49.280 678 678 678 678 678 678 678 679 619 679 619 679 679 619 680 680 680 680 æ д ω ф ம் Ω ф ф Д HIS HIS HIS ILE ILE ILE ILE 1853 1854 1855 1855 1856 1860 1861 1864 1867 1866 1867 1870 1871 1873 1873 1846 1847 1848 1849 1850 1877 1878 1879 1880 1881 1882 .883 

72

8.58 9.60 10.07 9.03 1.000 1. 1.00 21.858 22.897 22.431 15.661 17.107 4.499 20.621 19.482 19.089 -5.428 -6.900 -5.949 -6.672 -6.590 -6.158 -5.766 -7.629 -8.912 -6.939 -5.923 -4.513 -4.143 -6.971 -7.845 -7.674 -5.331 -5.561 -6.426 47.427 50.485 51.117 50.996 50.646 48.706 50.887 51.776 49.664 50.010 50.082 48.604 41.368 41.793 46.291 681 681 681 682 682 682 682 682 682 683 683 683 683 683 683 683 683 TRP TRP THR THR THR PHE PHE 1891 1892 1918 1919 1920 1922 1921 1923 1924 1925 1926 1927 1928 1929

ATOM

ATOM ATOM ATOM ATOM ATOM ATOM ATOM

12.07 14.13.76 13.76 13.76 13.76 13.76 13.76 13.76 13.76 10.02 10.02 13.76 10.02 10.02 13.76 10.02 10. 1.00 1.00 1.00 1.00 1.00 1111 25.090 22.317 22.604 21.897 21.793 21.429 20.934 21.781 21.781 21.781 21.781 21.781 21.781 21.7781 20.897 18.692 17.502 17.143 16.252 19.119 19.017 19.673 20.069 20.687 19.723 20.415 21.085 21.812 26.139 22.883 25.193 18.791 24.062 0.616 0.303 -0.783 0.473 -0.557 -0.557 -1.518 -0.754 0.216 -0.216 0.139 -0.907 -1.890 -3.058 -1.098 2.012 1.272 2.296 1.084 46.095 47.843 48.776 50.212 51.124 51.758 52.481 52.481 52.355 51.509 48.241 46.325 45.818 47.650 46.597 44.7.531 47.531 47.531 46.784 48.012 46.448 45.871 45.839 44.898 42.762 41.445 43.962 43.227 45.030 46.488 41.142 45.360 989 687 687 688 688 688 688 688 688 688 688 687 687 687 687 GLIN GLIN HIS HIS HIS HIS HIS 1941 1942 1943 1944 1945 1946 1930 1931 1932 1933 1934 1935 1936 1938 1939 1939 

113.46 111.32 111.32 112.33 111.49 112.32 111.32 111.32 111.32 111.32 112.35 113.10 112.35 113.10 112.35 113.10 11 1.00 1.00 1.00 1.00 1.00 16.071 17.795 17.054 15.982 17.925 17.749 18.968 19.276 18.712 19.800 20.038 20.038 16.481 16.015 17.481 16.015 17.644 11.6481 11.6015 11.6481 3.763 3.941 3.845 3.845 3.845 3.941 3.941 5.296 6.34 6.34 6.135 6.135 6.181 6. 49.824 50.774 50.583 51.722 46.173 45.826 45.346 43.892 43.892 43.892 43.456 44.790 44.790 44.790 44.273 43.456 42.342 44.958 44.958 44.958 44.958 44.958 44.958 44.958 44.958 44.958 44.958 44.958 692 692 692 692 692 1976 

442.537 462.079 460.705 339.066 339.0709 339.0709 339.0709 339.0309 330.077 340.077 34 NATIONALI NATION 

2.22 2.22 2.20 2.20 2.20 2.20 2.00 1.00 17.919 17.322 14.340 14.300 12.634 11.683 11.524 10.990 10.068 9.205 8.644 14.019 12.691 12.051 13.051 8.079 10.357 8.471 10.829 12.002 13.974 -4.994 -5.695 -7.724 -8.095 -6.779 -5.650 -7.654 -4.450 5.398 -8.161 4.162 2.903 3.020 5.243 -3.462 2.006 38.954 39.607 37.737 38.202 37.055 35.965 36.140 34.860 39.449 40.548 39.392 38.897 40.241 38.418 37.475 41.896 38.869 699 699 699 699 700 700 700 700 701 701 701 702 702 702 702 702 702 702 702 702 703 703 2058 2059 2060 2061 2061 2092 2093 

7.58 8.07 7.84 7.60 8.87 7.32 14.24 11.08 10.44 10.66 10.66 10.39 10.40 10.36 8.24 11.29 8.08 7.47 9.02 9.66 8.53 14.70 16.47 17.64 19.35 14.93 18.00 18.18 16.13 1.00 1.00 1.00 1.00 1.00 00. 00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 12.207 11.262 10.059 10.290 8.683 8.938 10.826 10.558 10.802 10.487 10.175 8.466 13.873 15.246 11.592 12.848 11.297 15.460 13.807 13.991 13.401 13.083 8.799 13.507 9.981 12.501 -7.837 -5.697 -10.805-10.798 -8.169 -9.959 -6.052 -7.931 -7.823 -9.654 -10.563 -12.000 -12.858 -12.174 -11.675 39.832 42.471 40.198 44.439 45.622 47.649 39.124 45.637 44.936 48.520 47.296 47.061 44.763 46.226 47.837 48.273 47.321 16.091 45.246 49.789 46.870 7004 7005 7005 7005 7005 7005 7005 7006 7008 MET MET MET MET MET MET 2098 2099 2100 2101 2101 2103 2104 2106 2107 2107 2108 2109 2109 2111, 2112, 2113, 2113, 2115 2116 2116 2117 2118 2120 2120 2121 2123 2123 2123 2124 2125 2126 2129 2130 2131 2132 2128 2133 ATOM

16.83 15.62 17.22 18.82 13.88 20.88 23.68 27.09 27.73 26.49 18.91 23.93 26.62 25.43 25.92 31.65 35.08 37.06 25.93 26.93 26.50 17.41 26.01 37.63 26.43 27.09 26.16 26.17 1.00 12.496 6.013 10.224 9.676 11.024 11.848 13.493 15.796 13.926 12.455 11.615 11.571 9.970 8.055 5.640 14.417 16.876 16.632 16.319 13.783 13.049 9.272 7.008 12.271 11.516 10.875 4.488 10.631 11.736 .2.437 2.651 10.157 3.464 -10.107 -10.643 -10.585-10.673-13.122 -13.303 -15.179 -14.544 -15.723 -15.029-12.746 -11.436 -11.607 -12.463 -13.092 -10.659-13.097 -12.677 -13.241-11.968 -9.365 -10.776 -13.072-13.206 50.587 53.937 53.288 53.705 51.936 53.214 55.171 52.598 52.745 54.847 53.286 53.453 54.827 52.808 52.091 50.569 54.430 55.390 57.790 56.900 58.141 54.392 55.467 54.261 54.103 54.896 56.825 58.181 56.913 58.631 59.795 57.697 709 CYS B 712 LYS B 713 710 710 710 711 711 711 711 711 711 711 712 712 712 712 712 714 714 714 Д ф ф ф Д CYS CYS GLY GLY TLE ILE HE ILE LE CXS CYS VAL VAL **VAL** VAL VAL VAL LYS LYS CO11 CO11 CG2 CORPE 2144 2145 2146 2147 2148 2149 2150 2151 2152 2143 2153 2154 2155 2156 2157 2158 2159 2159 2161 2162 2163 2163 2164 2166 2168 2169 2170 2172 2173 2175 2171 2174 2176 2177 2178 2179 ATOM ATOM

34.01 36.77 30.24 32.52 32.68 31.23 33.04 34.05 33.06 33.60 32.07 33.96 33.35 34.12 32.76 34.30 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.00 13.008 13.325 11.749 10.639 10.599 9.764 10.234 8.516 9.773 11.204 11.142 12.311 13.620 12.222 9.860 9.616 9.035 7.739 6.831 -20.482 -19.604 -19.452 -18.581 -20.122 -19.624 -17.477 -19.601 -17.40954.799 55.411 52.865 54.251 53.776 54.148 57.185 53.501 53.906 53.353 53.839 52.432 51.974 51.249 48.096 47.220 47.761 50.012 49.590 2208 2209 2210 2211 2212 2215 2216 2217 2218 2219 2220 2221 2213 2214 ATOM ATOM ATOM ATOM ATOM

29.36 31.20 31.53 23.23 23.64 21.64 20.50 20.86 22.30 27.29 29.38 30.03 27.24 25.84 25.19 35.80 37.91 36.85 26.12 30.46 17.88 16.10 16.51 13.98 18.10 19.81 20.17 1.00 1 1 00 1 . 00 1 . 00 1 . 00 1.00 1.00 1.00 1.00 1.00 4.896 4.368 4.578 3.958 4.948 6.625 6.050 2.952 2.337 0.986 -1.015 -0.529 6.792 4.532 0.169 3.276 3.235 4.117 5.090 5.626 4:560 5.134 4.011 4.187 6.895 6.822 -12.422 -10.361 -14.443 -15.203-17.782 -19.065 -16.916 -17.465 -18.462 -16.961 -17.236-19.242-20.036 -18.301 46.347 47.117 45.957 46.005 44.870 47.017 43.008 43.524 44.265 43.363 42.052 43.670 45.750 44.714 43.762 45.479 41,997 42.789 44.728 46.885 44.888 42.937 43.614 44.086 44.530 44.556 720 721 721 723 723 723 723 PHE B LYSS B LILE B LYS LYS PHE PHE PHE PHE PHE PHE PHE 2245 2246 2247 2248 2249 2250 2251 2252 2253 2255 2256 2257 2258 2260 2261 

	•	の養物とある		٠.															· .				•		٠				¥		``. V;		• •	分養者						
• ••	U	.:			×		ບ	0	บ		0	- · · · · · · · · · · · · · · · · · · ·		ט	ט	0		ט	ت.	ט	· ·	ט	ט		Ü	 U		0	Z 1		 	າ. ຕ	. i	N	ט	0	. 12		ט	· · ·
	.00 18.		1.00 17.09	.00 17.	.00 16.	.00 15.4	.00 15.	.00 15.2	.00 14.2	.00 14.3	.00 13.7	.00 13.0	.00 12.5	.00 12.8	,00 12.9	.00 11.8	.00 I3.3	.00 13,3	.00 12.8	.00 11.2	9.6 00.	.00 5.7	.00 7.0	.00 7.4	.00 5.9	.00 7.3	.00 13.3	.00 12.4	.00 13.9	2.CT 00.	0 18.2	.00 21.1	.00 25.7	.00 24.2	.00 15.7	.00 14.8	0 16.2	.00 17.1		0 20.
	<u> </u>	י ל	5.615	Ħ.	ŏ	Ö	'n	H	39.	4	Š	4	.78	9	m	7.	2	9	H	4	0.73	2	0.03	0.27	7.	4	1	8	80 7	7 6	4	27	75	57	9	97	77	67	13	03
	0.049 -14.01 8 846 -14 38	אם כני סני ט	38.878 -15.563	7.783 -15.36	9.216 -16.71	8.304 -17.86	8.983 -19.08	9.725 -18.63	7.963 ×19.9	7.769 -18.25	5.600 -18.61	3.621 -18.2	3.182 -18.54	9.394 -18.65	7.235 -17.44	5.101 -17.70	7,716 -16.19	5.915 -15.04	7.560 -13.73	5.773 -12.49	5.790 -11.93	5.061 -10.79	5.323 -10.22	1.579 -9.07	3.308 -10.76	3.036 -11.87	.496 -15.20	1.562 -15.00	.355 -15.59	085 - 16 31	.768 -15.	.356 -15.84	.021 -17.14	8	.100 -16.56	884 -16.37	.659 -17.55	.847 -18.4	.624 -19.64	.778 -20.6
	2266 CB VAL B 725	CG2 VAI. B 77	C VAL B 72	O VAL B 72	N THR B 72	CA THR B 72	CB THR B 72	OG1 THR B 72	CG2 THR B 72	C THR B 72	O THR B 72	N ALA B 72	CA ALA B 72	CB ALA B 72	C ALA B 72	O ALA B 72	N TYR B 72	CA TYR B 72	CB TYR B 72	CG TYR B 72	CD1 TYR B 72	CEI TYR B 72	CZ TYR B 72	OH TYR B 72	CE2 TYR B 72	. CD2 TYR B 72	C TYR B 72	O TYR B 72	N LYS B 72	CB LYS B 72	CG LYS B 72	CD LYS B 72	CE LYS B 72	NZ LYS B 72	C LYS B 72	O LYS B 72	N ASP B 73	CA ASP B 73	CB ASP B 73	CG ASP B 73
	ATOM															ATOM 2				ATOM 2							ATOM 2		-		ATOM . 2								ATOM 2	

15.48 22.24 26.72 31.50 16.47 17.37 21.53 16.47 18.51 17.81 19.79 31.30 32.86 15.27 21.62 22.67 20.57 19.72 18.38 18:15 17.76 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000 1.00 1.00 10.914 11.429 11.392 12.522 13.052 10.986 14.022 12.326 12.109 14.367 11.762 12.620 12.293 13.462 13.400 13.870 14.608 11.077 10.568 10.626 9.525 7.666 13.008 15.072 13,863 9.274 8.210 7.676 14.614 6:466 -15.595 -13.592 -12.894 -11.520 -10.622 -10.792-9.962 -10.387 -11.463 -11.070 -11.898 -9.967 -11.198 -10.096 30.846 28.444 28.872 27.003 34.775 28.075 28.931 28.964 30.649 27.732 30.066 28.578 30.392 32.343 30.555 29.874 31.403 32.566 30.998 29.366 30.276 29.161 29.805 PRO B 732
PRO B 733
PRO B 733
PRIS B 734
PRIS B 734 731 731 731 732 732 732 732 732 732 733 LEO LEO LEO LEO ASP ASP LEU LEU LEU LEU VAL VAL 2313 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2325 2327 2328 2329 2332 2333 2333 2333 2312 2334 2335 2336 2337 2338 2339 2340 2342 2343 2345 2341 ATOM ATOM ATOM ATOM ATOM ATOM ATOM ATOM ATOM ATOM

34.03 27.73 13.09 13.18 11.57 10.08 8.74 9.41 2.00 12.04 13.84 11.66 12.82 20.16 13.62 14.17 14.68 1.000 1.00 1.00 1.00 1.00 1.00 1.00 -6.653 -5.946 -6.349 -5.661 -7.314 -8.893 -11.414 -12.157 -11.832 -4.035 -6.065 -6.472 -6.403 30.162 30.615 34.206 35.063 34.224 35.257 34.999 33.648 35.757 36.728 

 дан
 136

 дан
 136

 дан
 136

 дан
 136

 дан
 136

 дан
 136

 дан
 137

 дан
 137

 дан
 137

 дан
 137

 дан
 137

 дан
 137

 дан
 138

 дан
 139

 739 739 739 739 739 2355 2356 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2373 2374 2375 2375 2377 2377 2377 2378 2378 2378 2378 2382 2383 23.85 ATOM ATOM

14.08 16.23 16.17 25.62 25.67 13.80 12.81 13.97 14.00 13.17 13.99 13.44 16.65 19.65 17.49 17.60 20.53 24.04 22.67 23.74 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 4.687 5.988 2.069 5.411 4.413 4.096 4.950 3.687 3.160 3.338 2.930 2.193 -1.379 -0.966 -2.118 -1.966 -1.627 0.928 2.281 3.196 1.807 0.039 4.624 5.415 5.284 1.710 0.426 4.733 0.101 1.514 7.102 37.470 37.968 36.920 36.797 35.330 35.008 33.588 33.531 34.096 33.733 37.245 36.469 38.519 39.089 40.118 39.695 39.671 39.698 40.175 39.640 39.291 39.320 42.072 43.492 43.902 40.177 44.797 VAL 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2404 2405 2403 2427 2428 2429 

25

35.03 35.68 39.53 42.51 47.78 34.47 36.86 33.35 31.94 32.95 33.35 39.89 39.89 39.77 41.92 27.13 31.92 27.13 31.92 27.18 31.92 27.18 31.92 27.18 31.92 27.18 31.92 27.18 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 3.574 1.542 1.767 0.995 -0.457 -0.514 1.439 2.266 0.234 1.439 2.266 0.234 -0.115 -0.928 -1.625 -1.625 -1.509 -2.600 -2.600 -3.728 -1.509 -1.509 -1.509 -1.509 -1.509 -1.509 -1.509 -1.509 -1.509 -1.509 -1.509 -1.509 -1.509 -1.509 -1.509 -1.509 -1.509 -1.500 -1.509 -1.50 8.889 8.457 9.456 10.733 10.872 9.880 8.364 8.925 8.925 8.925 8.925 8.925 8.925 8.925 8.925 8.925 10.125 10.735 10.153 11.772 3.480 1.305 1.027 1.979 3.290 4.167 4.657 2.427 1.563 0.192 .607 42.519 39.726 38.844 39.526 38.245 37.090 35.781 34.720 35.781 34.720 35.781 36.747 40.251 41.666 42.369 41.560 40.892 748 748 748 748 748 748 748 747 747 747 11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.12.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8

11.13.8 2441 2442 2443 2439 2440 24448 24449 24449 24510 24510 24510 24510 24510 24510 24510 24610 24610 24610 24610 24610 24610 24610 24610 24610 2444 2445 2446 2438 

16.66 15.69 14.91 15.07 15.52 15.02 15.22 15.23 14.48 15.87 14.29 15.94 16.82 15.32 15.05 16.49 17.73 17.48 14.19 13.40 13.15 12.76 17.13 13.73 00.1 00.1 L.00 00.1 1.00 1.00 1.00 1.00 1.00 ..... 1.00 1.00 1.00 1.00 1.00 00.1 00.1 00.1 ..00 00.1 00.1 00.1 00.1 ..00 00: 00.1 00: 00: 2.189 0.502. -0.960 -1.874 -0.580 0.545 -1.023 -0.198 0.976 -0.953 1.138 2.083 3.367 4.387 5.805 6.917 2.186 2.011 0.834 1.137 1.672 0.387 0.669 1.938 1.656 1.862 2.528 -7.795 -7.928 -5.512 -5.155 -3.490 -5.264 -5.642 -9.193 -3.593 -1.679 -1.299 -6.089 -3.110 -2.927 -5.478 -6.392 -6.937 -6.495 -7.320 -6.656 -6.847 -10.051 -4.772 -2.757 -1,366 -2.657 -1.884 43.683 41.534 41.594 42:277 42.760 46,016 46.830 47.876 40.606 43.138 42.790 42.236 42.606 41.941 44.984 44.803 46.481 47.962 46.811 45.977 46.516 45.829 47.807 45.863 45.849 46.219 45.975 46.222 46.863 41.067 750 750 750 750 750 750 751 751 751 752 752 752 752 752 753 753 753 753 753 753 751 751 751 752 752 754 754 754 754 754 ф В SER SER SER ILE ILE ILE ILE ASP ASP ASP SER SER SER ASP ILE ILE VAL yal val VAL VAL 2500 2504 2505 2506 2508 2509 2510 2511 2478 2479 2480 2482 2483 2484 2485 2486 2487 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2502 2503 2507 2512 2513 2477 24.81 ATOM ATOM

-6.674
-3.564
-2.764
-3.880
-3.880
-4.070
-5.936
-1.860
-1.337 52.012 53.166 51.935 50.782 49.988 50.386 51.213 51.770 51.770 51.320 52.419 50.210 50.210 

υt	ט ט	บ	Ö	ט	ט	0	Z	U	:	ບ	ໝ	ບ	U	0	Z	ט	ບ	ບ	ບ	0	N	ט	0	N	ט	ບ	ບ	ซ	z	บ	z	Ä	ບ	0	N	ט	บ	ບ	บ	บ
1.00 14.87	0 13.0	.00 13.	L.	0 13.8	1.00 16.61	1.00 16.43	1.00 18.47	1.00 21.12	2.4	24.5	0 32.	3.0	0 21.2	22.1	2.5	1.00 22.90	1.00 23.18	27	3	.00 3	36	.00 21	.00.21	.00 21	1.00 22.55	.00 23	.00 27	.00 31.	.00 36.	39.	.00 36.	°.	.00 22.	1.00 19.77	ω.	0 23.	4.	1.00 24.36	4.	0 24.
10.234	2.3	8	æ	9.0	.24	•	4.	8.631	.45	•	.77	.46	.81	9.533	8.159	8.259	7.106	5.714	5.279	4.658	5.585	9.593	10.247	O	11.232	-	2.7	2.93	. 12	2.4	3.6	11.691	₹.	13.438	ω.	.38	13.594	.09	13.885	. 52
-2.965	ī	4	4	3.91	.16	0			m,	w.	-4.025			-1.132	-0.005	1.171	2.123	1.393	0.617	1.172	-0.687	1.853	2.236	2.011	2.728	3.037	3.636	90	-	18	78	91	94	Ŋ	Ø	26	-1.301	-0.718	ø	4
48.414	7.23	8.11	.16	•	. 78	.33	. 42	.79	.26	.77	.03	.13	.68	•	•	54.223	53.913	53.783	55.041	55.947	55.071	54.043	54.985	52.815	52.622	51.143	50.785	51.197	50.298	49.055	48.603	œ	ന	ന	53.190	3.58	2.50	1:1	٠	1.3
CG PHE B 760	B 76	PHE B	PHE B		PHE B	PHE B	MET B 7	MET B	MET B	MET B	MET B	MET B	MET B	MET B	GIN B	GI'N B	GIN B	GLN B	GLN B	• •	GLN B	GLN B	GIN B	ARG B	ARG B	ARG B	ARG B	ARG B	ARG B	CZ ARG B 763	ARG B	HZ ARG B	ARG B 7	ARG B		LEU B	CB LEU B 764	LEU B 7		CD2 LEU B 764
2560	2562	2563	2564	2565	2566	2567	2568	2569	2570	2571	2,572	2573	2574	2575	2576	2577	2578	2579	2580	2581	2582	2583	2584	2585	2586	2587	2588	2589	2590	2591	2592	2593	2594	2595	2596	2597	2598	2599	2600	2601
ATOM ATOM	ATOM	ATOM .	ATOM	ATOM	ATOM	ATOM	ATOM		ATOM		ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM	ATOM

.

31.61 33.54 33.93 36.39 40.65 34.71 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 13.698 15.802 15.610 16.119 16.083 12.879 13.377 13.273 14.424 14.840 17.232 17.768 18.545 16.985 17.816 20.094 14.309 12.981 0.013 -0.872 -1.570 -1.892 -2.945 -1.456 -3.092 -5.237 -4.966 -6.683 -3.895 59.559 58.982 57.496 57.796 58.254 58.126 58.966 58.966 59.909 58.615 59.035 59.449 57.398 56.992 55.652 55.048 56.926 57.394 56.239 55.621 55.142 56.354 54.504 765 

00020000 38.45 35.23 34.31 33.76 35.17 44.15 43.36 48.39 50.30 34.71 46.14 48.34 50.02 52.64 54.66 54.48 55.08 56.17 59.18 59.51 1.00 19.380 19.610 19.304 23.668 22.090 19.144 19.229 18.775 19.354 21.169 20.343 20.752 19.061 18.576 18.441 17.454 16.620 15.432 19.238 20.662 17.175 18.383 17.425 20.320 21.187 19.879 19.768 .9.901 18.355 -7.426 -6.431 -5.418 -8.189 -6.041 -7.004 -7.467 -8.888 -8.307 -8.723 -9.775 -10.968 -5.491 -9.932 -9.113-10.356 -11.413 -9.510 -9.181 -9.024 -11.173-13.432-11.447 57.116 61.077 58.911 58.610 55.729 54.776 54.263 56.175 53.309 62.368 62.956 54.703 55:641 59.572 61.159 60.235 62.746 63.884 65.106 63.691 64.694 59.703 61.590 64.021 770 770 770 770 771 771 771 771 771 771 771 771 772 772 772 772 771 771 771 773 773 773 773 773 GLN GLIN GLIN TYR TYR TYR TYR 2648 2649 645 2646 3647 2650 2651 2652 2653 2654 2655 2656 2657 2672 2673 2674 2675 2676 2677 2679 2678 2680 2681 2682 

55.28 55.27 55.36 56.03 56.21 56.21 52.28 52.28 51.05 51.05 49.65 49.64 47.40 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 26.817 25.804 26.404 25.321 24.271 24.291 24.508 26.737 27.466 26.983 28.117 28.526 28.693 29.916 27.702 27.460 27.595 27.199 27.488 27.483 25.369 -8.103 -10.337-9.364 -7.973 -11.917 62.577 59.846 60.560 58.638 58.011 57.078 56.561 57.189 56.916 56.810 55.960 56.128 57.514 55.525 54.508 57.807 54.098 52.748 776 776 776 776 777 777 7777 777 778 778 778 778 778 778 LEU LEU SER SER SER SER 3688 2689 2690 2692 2693 2694 2695 2691 ATOM ATOM ATOM ATOM ATOM ATOM ATOM

41.48 40.81 40.94 41.63 40.96 41.15 41.28 42.88 40.06 41.74 42.10 41.40 43.09 42.35 40.74 41.64 41.11 45.68 48.44 49.03 51.46 53.83 49.08 50.08 54.84 53.76 49,44 51.26 51.67 50.78 1.00 1.00 00.1 1.00 1.00 ١.00 . 00 1.00 1.00 1.00 1.00 00.1 1.00 ..00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 H H H H ... 1.00 1.00 1.00 1.00 31.060 29.620 29.606 28.886 26.509 27.311 27.497 29.063 28.961 28.388 30.932 29.579 28.374 30.413 31.708 32.656 35.137 32.048 28.000 37.122 29.710 28.967 29.879 33.902 35.248 29.563 36.446 31.879 36.322 31.746 31.075 28.831 27.347 31.643 -7.730 -7.626 -6.369 -8.528 -6.295 -8.859 -10.140 -10.590 -9.353 -12.125 -9.990 -9.749 -7.961 -12.601 -12.473 -12.667 -10.093 -9.334 -9.080 -9.692 -10.450 -11.490 -10.203-11,356 -11.180 -10.507 -12.545-13.068 -12.109 -13.299 -11.552 -13.007 -12.97147.066 48.136 45.321 45.027 46.795 5.775 44.174 44.169 42.817 42.923 41.877 40.617 40.666 41.830 39.720 38.831 38.178 46.953 39.719 40.049 39.388 38.390 37.583 42.915 39.907 38.870 39.506 38.559 39.185 38.331 37.169 36.409 36.100 35.162 35.332 781 781 782 782 782 782 782 782 782 782 783 783 783 781 781 783 783 783 781 781 784 784 784 784 784 784 784 784 784 785 д ф ф PRO 3 PRO ILE TLE TLE TILE PRO PRO PRO PRO PRO HIS HE TIE. ILE PRO HIS HIS HIS HIS HIS HIS HIS ILE TLE HIS ILE CD1 CG2 CG1 CD1 CG2 00 z 5 5 2730<sup>2</sup> 1729 2728 2732 2733 2734 2735 2736 2738 2739 2740 2741 2742 2744 2744 2744 2746 2746 2747 2750 2752 2752 2753 2754 2753 2754 2753 2754 2754 2755 2756 2757 2757 2758 2737 2759 2760 2761 2762 2763 2765 ATOM ATOM

47.41 48.66 46.60 47.13 45.50 49.77 44.51 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1:00 29.991 28.897 28.935 28.970 28.549 33.165 30.109 27.910 26.866 25.896 27.200 28.288 -i5.085 -13.138 -15.489 -16.389-15.482-13.883 -11.911 20.931 22.180 23.030 30.800 22.266 22.987 23.458 24.423 24.287 26.093 22.417 25.177 26.077 B .786 B 786 786 787 787 787 787 787 787 787 B 787 B 787 ARG
ARG
ARG
ARG
ARG
ARG
ARG
ARG
ARG
ARG ARG ARG LEU LEU LEU LEU LEU ASP ASP ASP ASP ASP ASP ASP LEG ASP TYR TYR TYR TYR TYR TYR TYR CD1 2777 2779 2780 2782 2783 2772 2773 2776 2781 2784 2785 2789 2790 2791 2.792 2.793 2794 2795 2796 2797 2798 2799 2799 2801 2802 2809 2810 2811 2803 2804 2805 2806 2807 2808 ATOM ATOM

94

26.64 27.32 21.47 21.22 18.47 16.23 13.89 11.09 11.98 21.26 21.67 21.32 22.19 21.62 23.30 25.82 21.99 21.51 25.46 26.11 24.70 1.00 1.00 1.00 1.00 1.00 00: 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 28.820 29.600 28.690 29.349 29.910 30.917 28.926 31.590 32.298 32.468 30.598 30.271 29.595 33.494 33.152 32.631 32.578 32.806 32.769 33.664 32.170 34.114 33.919 35.099 32.917 34.061 33.585 34.191 35.032 38.551 14.234 36.323 36.472 37.240 38.887 -8.268 -7.522 -6.707 -7.912 -8.571 -7.405 -7.505 -6.919 -6.357 -5.790 -5.609 .-2.528 -2.406 -0.859 -7.412 -6.414 -2.099 -6.754 -8.091 -8.475 -6.167 -6.195 -3.926 -4.502 -2.897 0.211 0.562 -1.497 1.422 -2.254-3.421 -1.567-1.01530.980 31.453 26.881 25.501 27.773 25.193 23.182 24.471 28.197 28.058 30.831 31.865 26.339 28.709 23.887 29.109 29.724 29.556 30.859 22.881 29.651 29.543 28.154 27.814 29.817 29.437 30.492 33.179 . Начачачачач д HIS HIS HIS HIS HIS PHE GLY GLY LEU 問证 GLY LEU LEU GLU LEU GLU GLU GLU CE2 CE2 CE2 CD2 2816 2818 819 2820 2817 2822 2829 2830 2836 2837 2821 2823 2824 2825 2826 2827 2828 2831 2832 2833 2834 2835 2838 2839 2840 2841 2842 2843 2845 2846 2844 2847 2848 2849 2850 2851 2852 2853 2854 ATOM ATOM

26.02 26.65 24.35 26.05 21.13 19.86 11111 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 41.209 44.294 42.418 38.922 37.748 45.314 37.875 36.852 36.631 36.281 38.516 38.653 32.979 12.153 38.005 1.696 2.598 3.806 2.024 2.612 1.859 2.296 0.824 2.753 1.758 3.855 3.895 2.791 4.880 4.734 5.570 5.451 6.275 5.763 5.983 7.051 7.769 28.826 27.826 30.033 29.073 29.952 31.459 32.325 33.486 31.853 27.603 26.905 27.131 25.766 25.766 26.404 24.156 22.680 22.680 22.333 23.048 24.156 NEW CONTRACTOR OF THE CONTRACT 2884 2885 2886 2886 2888 2888 2889 2893 ATOM ATOM ATOM ATOM

31.05 20.34 18.49 22.07 24.13 18.61 80: 1.00 00.1 1.00 00.1 1.00 00.1 1.00 .00 1.00 1.00 1.00 00.7 1.00 00: 00: 28.432 30.688 32.264 31.843 30.789 29.158 34.576 32,351 31.674 30.490 33.752 31.714 31.553 32.121 31.531 31.691 38.917 38.549 11.799 8.878 12.033 12,741 12.403 9.689 13.079 12.999 9.619 10.216 11.583 9.321 11.351 12.557 9.319 10.465 7.620 5.590 8.678 8.168 6.068 8.700 9.266 8.078 8.009 7.006 4.583 5.334 9.373 8.388 24.160 27.470 29.152 27.160 25.668 25.128 27.423 24.662 26.583 28.893 28.067 27.482 27.817 26.903 29.205 28.287 24.659 24.142 28.964 29.419 29.888 28.383 ASP ASP PHE ASP LEU LEU LEU PHE PHE PHE PHE PHE PHE ASP LEU ARG ARG ARG ASP ASP ASP LEU LEU ASP ASP ASP ASP 002 2929 2933 2934 2935 2936 2928 2930 2932 2922 2925 2927 2931 2915 2919 2920 2921 2924 2926 2910 2914 2917 2918 2906 2907 2908 2909 2913 2900 2903 2904 2905 2911 2912 2901 2902 ATOM atoń ATOM

## Claims

1. A crystal structure of the pRb/E2F<sub>(409-426)</sub> complex, characterised by the atomic co-ordinates of Annex 1.

5

2. A crystal structure as claimed in claim 1, wherein the interactions between E2F<sub>(409-426)</sub> and pRb comprise one or more of the following interactions:

E2F <sub>(409-426)</sub> residue	pRb residue
Leu <sub>409</sub>	Lys <sub>548</sub>
Tyr <sub>411</sub>	Glu <sub>551</sub>
Tyr <sub>411</sub>	Ile <sub>532</sub>
Tyr <sub>411</sub>	Glu <sub>554</sub>
His <sub>412</sub>	Arg <sub>656</sub>
His <sub>412</sub>	Lys <sub>653</sub>
Gly <sub>414</sub>	$Glu_{533}$
Gly <sub>414</sub>	Lys <sub>652</sub>
Leu <sub>415</sub>	Leu <sub>649</sub>
Leu <sub>415</sub>	Glu <sub>553</sub>
Leu <sub>415</sub>	Lys <sub>537</sub>
Glu <sub>417</sub>	Lys <sub>537.</sub>
Gly <sub>418</sub>	Aŕg <sub>467</sub>
Glu <sub>419</sub>	Thr <sub>645</sub>
Arg <sub>422</sub>	Glu <sub>464</sub>
Asp <sub>423</sub>	Arg <sub>467</sub>
Leu <sub>424</sub>	Lys <sub>530</sub>
Phe <sub>425</sub>	Phe <sub>482</sub>
Phe <sub>425</sub>	Lys <sub>475</sub>

- 3. An assay to identify an agent which modulates the interaction between pRb and E2F<sub>(409-426)</sub>, the assay comprising:
- a) combining together pRb, E2F<sub>(409-426)</sub> and an agent, under conditions in which pRb and E2F<sub>(409-426)</sub> form a complex;
  - b) obtaining a crystal structure of any pRb/ E2F<sub>(409-426)</sub> complex; and
- c) analysing the crystal structure to determine whether the agent is an agent which modulates the interaction between pRb and E2F<sub>(409-426)</sub>.
  - 4. An assay, as claimed in claim 3, wherein the combining of the components is pRb with the agent and then  $E2F_{(409-426)}$ .
- 5. An assay as claimed in claim 3, wherein the combining of the components is E2F<sub>(409-426)</sub> with the agent and then pRb.
  - 6. An assay as claimed in claim 3, wherein the combining of the components is pRb with  $E2F_{(409-426)}$  and then the agent.
  - 7. A method of identifying an agent that modulates a pRb/E2F<sub>(409-426)</sub> complex, comprising selecting an agent using the three-dimensional atomic coordinates of Annex 1.
- 25 8. A method as claimed in claim 7, wherein said selection is performed in conjunction with computer modeling.

20

9. A method as claimed in claim 7 or 8, wherein the method further comprises the steps of:



- a) contacting the selected agent with pRb and E2F<sub>(409-426)</sub> under conditions in which pRb and E2F<sub>(409-426)</sub> can form a complex; and
- b) measuring the binding affinity of pRb to E2F<sub>(409-426)</sub> in the presence of the agent and comparing the binding affinity to that of pRb to E2F<sub>(409-426)</sub> when in the absence of the agent, wherein an agent modulates a pRb/E2F<sub>(409-426)</sub> complex when there is a change in the binding affinity of pRb to E2F<sub>(409-426)</sub> when in the presence of the agent.
  - 10. A method as claimed in claim 9, wherein the method further comprising:
- a) growing a supplementary crystal from a solution containing pRb and E2F<sub>(409-426)</sub> and the selected agent where said agent changes the binding affinity of the pRb/E2F<sub>(409-426)</sub> complex under conditions in which pRb and E2F<sub>(409-426)</sub> can form a complex;

- b) determining the three-dimensional atomic coordinates of the supplementary crystal by X-ray diffraction using molecular replacement analysis;
- c) comparing the three dimensional coordinates with those for the complex as claimed in claim 1; and
- d) selecting a second generation agent using the three-dimensional atomic coordinates determined for the supplementary crystal.
- 11. A method as claimed in claim 10, wherein said selection is performed in conjunction with computer modeling.
- 12. A method of identifying an agent that modulates a pRb/E2F<sub>(409-426)</sub> complex, comprising:
- a) contacting a selected agent with pRb and E2F<sub>(409-426)</sub> under conditions in which pRb and E2F<sub>(409-426)</sub> can form a complex; and
- b) measuring the binding affinity of pRb to E2F<sub>(409-426)</sub> in the presence of the agent and comparing the binding affinity to that of pRb to E2F<sub>(409-426)</sub> when

in the absence of the agent, wherein an agent modulates a pRb/E2F<sub>(409-426)</sub> complex when there is a change in the binding affinity of pRb to  $E2F_{(409-426)}$  when in the presence of the agent.

- 5 13. A method as claimed in claim 12, wherein the method further comprising:
  - a) growing a supplementary crystal from a solution containing pRb and E2F<sub>(409-426)</sub> and the selected agent where said agent changes the binding affinity of the pRb/E2F<sub>(409-426)</sub> complex under conditions in which pRb and E2F<sub>(409-426)</sub> can form a complex;
- b) determining the three-dimensional atomic coordinates of the supplementary crystal by X-ray diffraction using molecular replacement analysis;
  - c) comparing the three dimensional coordinates with those for the complex as claimed in claim 1; and
  - d) selecting a second generation agent using the three-dimensional atomic coordinates determined for the supplementary crystal.
  - 14. A method as claimed in claim 13, wherein said selection is performed in conjunction with computer modeling.
- 15. A method of identifying an agent that modulates a pRb/E2F<sub>(409-426)</sub> complex, comprising:
  - a) selecting an agent;

- b) co-crystalising pRb with the agent;
- c) determining the three dimensional coordinates of the pRb-agent association by X-ray diffraction using molecular replacement analysis; and
- d) comparing the three dimensional coordinates with those of the complex as claimed in claim 1.

- 16. A method of identifying an agent that modulates a pRb/E2F<sub>(409-426)</sub> complex, comprising:
- a) selecting an agent;
- b) crystalising pRb and soaking the agent into the crystal;
- 5 c) determining the three dimensional coordinates of the pRb-agent association by X-ray diffraction using molecular replacement analysis; and
  - d) comparing the three dimensional coordinates with those of the complex as claimed in claim 1.
- 17. A method of identifying an agent that modulates a pRb/E2F<sub>(409-426)</sub> complex, comprising:
  - a) selecting an agent;
  - b) co-crystalising pRb, E2F<sub>(409-426)</sub> and the agent;
  - c) determining the three dimensional coordinates of the pRb-E2F-agent association by X-ray diffraction using molecular replacement analysis; and
  - d) comparing the three dimensional coordinates with those of the complex as claimed in claim 1.
  - 18. A method of identifying an agent that modulates a pRb/E2F<sub>(409-426)</sub> complex, comprising:
  - a) selecting an agent;
  - b) co-crystalising pRb and E2F<sub>(409-426)</sub> and soaking the agent into the crystal;
  - c) determining the three dimensional coordinates of the pRb-E2F-agent association by X-ray diffraction using molecular replacement analysis; and
- d) comparing the three dimensional coordinates with those of the complex as claimed in claim 1.

- 19. A method as claimed in any one of claims 15 to 18, wherein the methods further comprise selecting a second generation agent using the three dimensional atomic coordinates determined.
- 20. A method as claimed in claim 19, wherein the agent is selected using the three dimensional atomic coordinates of Annex 1.
  - 21. A method as claimed in claim 20, wherein the selection is performed in conjunction with computer modeling.
  - 22. A method of identifying an agent as claimed in any one of claims 7 to 21, wherein the selected agent and/or the second generation agent mimics a structural feature of  $E2F_{(409-426)}$  when said  $E2F_{(409-426)}$  is bound to pRb.
- 23. A method as claimed in claim 7 or 8, wherein method comprises the further steps of:
  - a) contacting the selected agent with the pRb/E2F<sub>(409-426)</sub> complex; and
  - b) determining whether the agent affects the stability of the complex.
- 24. A method as claimed in claim 23, wherein the determination is with fluorescence polarization.
  - 25. A method of identifying an agent that modulates a pRb/E2F<sub>(409-426)</sub> complex, comprising:
- a) contacting a fluorescently tagged E2F<sub>(409-426)</sub> peptide (E2F-fluoropeptide) with pRb to allow pRb/E2F-fluoropeptide complex formation;
  - b) detecting the fluorescence polarization;
  - c) adding a selected agent; and
  - d) detecting the fluorescence polarization in the presence of the agent.



- 26. A method of identifying an agent that modulates a pRb/E2F<sub>(409-426)</sub> complex, comprising;
- a) contacting a fluorescently tagged E2F<sub>(409-426)</sub> peptide (E2F-fluoropeptide) with pRb to allow pRb/E2F-fluoropeptide complex formation and detecting the fluorescence polarization;
- b) contacting a selected agent with pRb and E2F<sub>(409-426)</sub> peptide (E2F-fluoropeptide) under conditions in which pRb and E2F-fluoropeptide can form a complex, and detecting the fluorescence polarization; and
- c) comparing the fluorescence polarization detected in a) and b).

- 27. A method as claimed in claim 25 or 26, wherein a decrease in fluorescence polarization in the presence of the agent indicates that the agent destabilises the complex.
- 28. A method as claimed in any one of claims 25 to 27, wherein the method comprises the further step of adding untagged E2F<sub>(409-426)</sub> and detecting fluorescence polarization.
- 29. A method as claimed in claim 28, wherein if fluorescence polarization decreases, on addition of the untagged £2F<sub>(409-426)</sub>, the agent does not stabilise the complex.
  - 30. A method as claimed in claim 28 or 29, wherein if there is no substantial change in fluorescence polarization, on addition of the untagged E2F<sub>(409-426)</sub>, the agent stabilises the complex.
  - 31. A method as claimed in any one of claims 9 to 14, wherein the binding affinity is measured by isothermal titration calorimetry.


- 32. A method as claimed in any one of claims 9 to 14, wherein the binding affinity is measure by Surface Plasmon Resonance (SPR).
- 5 33. An agent, that modulates the interaction between pRb and E2F<sub>(409-426)</sub>, identified by a method as claimed in any one of claims 3 to 32.


1Ò

- 34. An agent, as claimed in claim 33, for use as an apoptosis promoting factor in the prevention or treatment of proliferative diseases.
- 35. An agent as claimed in claim 33 or 34, wherein the agent is for use in preventing or treating cancer, which may be pancreatic cancer and related diseases.
- 36. The use of an agent, which modulates the formation of a pRb/E2F<sub>(409-426)</sub> complex, identified by a method as claimed in any one of claims 3 to 32, in the manufacture of a medicament for the prevention or treatment of proliferative diseases.
- 20 37. The use of an agent as claimed in claim 36, wherein the proliferative diseases are cancer, preferably pancreatic cancer and related diseases.
  - 38. The use of the atomic co-ordinates of the crystal structure as claimed in claim 1 or 2, for identifying an agent that modulates the formation of a pRb/E2F<sub>(409-426)</sub> complex.
  - 39. Computer readable media comprising a data storage material encoded with computer readable data, wherein said computer readable data comprises a

set of atomic co-ordinates of the pRb/E2F<sub>(409-426)</sub> complex of Annex 1 recorded thereon.

11: 27










Figure 1C







Binding Constants (μΜ)	$\mathbf{R}\mathbf{b_{AB}}$	Rb <sub>ABC</sub>	
E2F (409-426)	0.34 ±0.02	0.3 ±0.03	
E2F (380-437)	0.16 ±0.01	0.1 ±0.01	
E2F (243-437)	<0.01	<0.01	

## This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

## IMAGES ARE BEST AVAILABLE COPY.

**□** OTHER: \_\_\_\_

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.